<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neuroinflammation</journal-id><journal-id journal-id-type="iso-abbrev">J Neuroinflammation</journal-id><journal-title-group><journal-title>Journal of Neuroinflammation</journal-title></journal-title-group><issn pub-type="epub">1742-2094</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22898493</article-id><article-id pub-id-type="pmc">3458954</article-id><article-id pub-id-type="publisher-id">1742-2094-9-199</article-id><article-id pub-id-type="doi">10.1186/1742-2094-9-199</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Pro-inflammatory interleukin-18 increases Alzheimer&#x02019;s disease-associated amyloid-&#x003b2; production in human neuron-like cells</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Sutinen</surname><given-names>Elina M</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>elina.sutinen@uef.fi</email></contrib><contrib contrib-type="author" deceased="yes" id="A2"><name><surname>Pirttil&#x000e4;</surname><given-names>Tuula</given-names></name></contrib><contrib contrib-type="author" id="A3"><name><surname>Anderson</surname><given-names>George</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>anderson.george@rocketmail.com</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Salminen</surname><given-names>Antero</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I4">4</xref><email>antero.salminen@uef.fi</email></contrib><contrib contrib-type="author" corresp="yes" id="A5"><name><surname>Ojala</surname><given-names>Johanna O</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>johanna.ojala@uef.fi</email></contrib></contrib-group><aff id="I1"><label>1</label>University of Eastern Finland, Institute of Clinical Medicine/ Neurology, Canthia, P.O.B. 1627, FI-70211, Kuopio, Finland</aff><aff id="I2"><label>2</label>University of Eastern Finland, Clinical Research Centre/ Brain Research Unit, Mediteknia, P.O.B. 1627, FI-70211, Kuopio, Finland</aff><aff id="I3"><label>3</label>CRC, Rm30, 57 Laurel Street, Glasgow, Scotland, UK</aff><aff id="I4"><label>4</label>Kuopio University Hospital, Neurology, P.O.B. 1777, FI-70211, Kuopio, Finland</aff><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>16</day><month>8</month><year>2012</year></pub-date><volume>9</volume><fpage>199</fpage><lpage>199</lpage><history><date date-type="received"><day>9</day><month>3</month><year>2012</year></date><date date-type="accepted"><day>28</day><month>7</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2012 Sutinen et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Sutinen et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.jneuroinflammation.com/content/9/1/199"/><abstract><sec><title>Background</title><p>Alzheimer&#x02019;s disease (AD) involves increased accumulation of amyloid-&#x003b2; (A&#x003b2;) plaques and neurofibrillary tangles as well as neuronal loss in various regions of the neocortex. Neuroinflammation is also present, but its role in AD is not fully understood. We previously showed increased levels of pro-inflammatory cytokine interleukin-18 (IL-18) in different regions of AD brains, where it co-localized with A&#x003b2;-plaques, as well as the ability of IL-18 to increase expression of glycogen synthase kinase-3&#x003b2; (GSK-3&#x003b2;) and cyclin dependent kinase 5, involved in hyperphosphorylation of tau-protein. Elevated IL-18 has been detected in several risk conditions for AD, including obesity, type-II diabetes, and cardiovascular diseases as well as in stress.</p></sec><sec><title>Methods</title><p>We differentiated SH-SY5Y neuroblastoma cells as neuron-like and exposed them to IL-18 for various times. We examined the protein levels of amyloid-&#x003b2; precursor protein (APP) and its processing products, its cleaving enzymes, involved in amyloidogenic processing of APP, and markers of apoptosis.</p></sec><sec><title>Results</title><p>IL-18 increased protein levels of the &#x003b2;-site APP-cleaving enzyme BACE-1, the N-terminal fragment of presenilin-1 and slightly presenilin enhancer 2, both of which are members of the &#x003b3;-secretase complex, as well as Fe65, which is a binding protein of the C-terminus of APP and one regulator for GSK-3&#x003b2;. IL-18 also increased APP expression and phosphorylation, which preceded increased BACE-1 levels. Further, IL-18 altered APP processing, increasing A&#x003b2;40 production in particular, which was inhibited by IL-18 binding protein. Increased levels of soluble APP&#x003b2; were detected in culture medium after the IL-18 exposure. IL-18 also increased anti-apoptotic bcl-xL levels, which likely counteracted the minor increase of the pro-apoptotic caspase-3. Lactate dehydrogenase activity in culture medium was unaffected.</p></sec><sec><title>Conclusions</title><p>The IL-18 induction of BACE-1, APP processing, and A&#x003b2; is likely to be linked to stress-associated adaptations in neurons during the course of normal functioning and development. However, in the course of wider changes in the aging brain, and particularly in AD, the effects of heightened or prolonged levels of IL-18 may contribute to the process of AD, including via increased A&#x003b2;.</p></sec></abstract><kwd-group><kwd>Interleukin-18</kwd><kwd>Inflammation</kwd><kwd>Amyloid-beta</kwd><kwd>Alzheimer&#x02019;s disease</kwd><kwd>BACE</kwd><kwd>Presenilin</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Alzheimer&#x02019;s disease (AD) is a neurodegenerative disorder, which is characterized particularly by accumulation of amyloid-&#x003b2; (A&#x003b2;) peptide in the brain parenchyma and in the walls of leptomeningeal and parenchymal vessels [<xref ref-type="bibr" rid="B1">1</xref>]. Neurofibrillary changes, neuronal loss, synaptic dysfunction, evidence of oxidative and excitotoxic damage as well as low grade inflammation are also present in the AD brain [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. Increased &#x00391;&#x003b2; production from intracellular amyloid precursor protein (APP) metabolism, are believed to initiate the pathogenic processes in AD. Inflammation also seems to have a role in the ethiopathogenesis of AD [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>], although it is not clear whether inflammation is a cause, contributor, or secondary phenomenon in the disorder [<xref ref-type="bibr" rid="B6">6</xref>]. There is also no clear causal connection between the up-regulation of pro-inflammatory cytokines and A&#x003b2; expression.</p><p>Over-expression of pro-inflammatory interleukins 1 and 6 (IL-1, IL-6) has been detected in the AD brain [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. Pyrogenic IL-1&#x003b2; can induce over-expression of APP [<xref ref-type="bibr" rid="B11">11</xref>] contributing to the generation of neuritic A&#x003b2;-plaques. We have found increased levels of another IL-1 family member, pro-inflammatory IL-18 (interferon-&#x003b3;-inducing factor, IL-1&#x003b3;), in AD brain [<xref ref-type="bibr" rid="B12">12</xref>]. Non-pyrogenic IL-18 has structural similarities with the IL-1 family of proteins and it can increase production of toxic inflammatory molecules such as IFN-&#x003b3; [<xref ref-type="bibr" rid="B13">13</xref>] and IL-1&#x003b2; [<xref ref-type="bibr" rid="B14">14</xref>]. IFN-&#x003b3;, via caspase-1 induction, cleaves the pro-forms of IL-1&#x003b2; and IL-18 to their active mature forms [<xref ref-type="bibr" rid="B15">15</xref>] and also increases levels of IL-18 [<xref ref-type="bibr" rid="B16">16</xref>], indicating that up-regulated IL-18 expression can lead to a harmful vicious cycle of inflammation, possibly also in the brain. IL-18 is produced primarily by activated microglia, but also by astrocytes and ependymal cells in the central nervous system (CNS) [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. IL-18 is also detectable in neurons [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>].</p><p>The IL-18 gene is located in the region 11q22.2-22.3 close to the dopamine receptor D2 locus. This region is near the tip of the long arm of chromosome 11, which has been reported as a suggestive linkage area for AD in AD families [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>]. Further, the IL-18 promoter contains multiple transcription initiation sites [<xref ref-type="bibr" rid="B16">16</xref>], and its polymorphism has been shown to be a risk of late onset AD [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. However, only single nucleotide polymorphisms (SNPs) at positions &#x02212;137 and &#x02212;607 have been confirmed to have an impact on IL-18 gene activity [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. Individuals with two copies of the IL-18 -607 C or &#x02212;137&#x02009;G allele have been found to have increased odds of developing AD and these associations were influenced by the presence of the ApoE &#x003f5;4 alleles, increasing the risk to develop AD more than five- and four-fold, respectively [<xref ref-type="bibr" rid="B23">23</xref>]. These alleles as well as &#x02212;607 C/-137&#x02009;G haplotype are associated with higher expression of the IL-18 gene and sustained higher levels of the cytokine [<xref ref-type="bibr" rid="B23">23</xref>]. However, Segat <italic>et al</italic>. (2010) could not find association between IL-18 gene promoter polymorphism (&#x02212;137&#x02009;G/C and &#x02212;607 C/A) and onset of AD [<xref ref-type="bibr" rid="B26">26</xref>].</p><p>Although no significant increase of circulating cytokines has been detected in AD patients [<xref ref-type="bibr" rid="B27">27</xref>], the levels of IL-18 mRNA in monocyte-macrophages of the peripheral blood has been shown to be high in AD-mild patients, slightly lower in AD-moderate patients, but not significantly different in AD-severe patients compared to non-demented age-matched subjects [<xref ref-type="bibr" rid="B28">28</xref>]. On the other hand, a significant increase in production of IL-18 has been obtained from lipopolysaccharide (LPS)-stimulated blood mononuclear cells of AD patients, and that was particular in AD patients carrying the &#x02212;607 C/C genotype of IL-18 promoter. In addition, a significant correlation between IL-18 production and cognitive decline was apparent in AD patients [<xref ref-type="bibr" rid="B27">27</xref>]. Therefore, the increase in the potency of these cells to respond to stimulation by LPS in AD patients may reflect the relative increase of inflammatory response. This may also occur in the brain in response to, for example, A&#x003b2;, since A&#x003b2;42 has been shown to prime at least dendritic cells to enhanced release of IL-1&#x003b2;, IL-6, and IL-18 [<xref ref-type="bibr" rid="B29">29</xref>].</p><p>Binding of IL-18 to its receptor in the CNS leads to activation of the transcription factor NF-&#x003ba;B via a complex intracellular cascade [<xref ref-type="bibr" rid="B30">30</xref>]. Via NF-&#x003ba;B activation, IL-18 can also activate both Fas and Fas-L promoter activities [<xref ref-type="bibr" rid="B31">31</xref>], which suggests the possibility that IL-18 may be one of the apoptosis-inducing factors contributing to neurodegeneration during AD progression. IL-18 can also modulate neuronal excitability [<xref ref-type="bibr" rid="B32">32</xref>] and IL-18, like IL-1&#x003b2; and TNF-&#x003b1;, inhibits long-term potentiation (LTP), a form of neuronal plasticity widely believed to underlie learning and memory, both in the early p38 mitogen activated protein kinase-dependent (MAPK p38) phase and the later protein synthesis-dependent phase [<xref ref-type="bibr" rid="B33">33</xref>].</p><p>The importance of IL-18 in APP synthesis and processing is unknown. Interestingly, increased levels of IL-18 have been found in the blood of patients with ischemic heart disease [<xref ref-type="bibr" rid="B34">34</xref>], type-2 diabetes, and obesity [<xref ref-type="bibr" rid="B35">35</xref>], which are all known risk factors for AD [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B37">37</xref>]. The links between these disorders and AD is not fully understood. IL-18 is also associated with stress [<xref ref-type="bibr" rid="B38">38</xref>] and regulates anxiety and fear memory in mice [<xref ref-type="bibr" rid="B39">39</xref>]. IL-18 levels are generally increased in Cushing&#x02019;s disease patients, where a significant positive correlation between IL-18 and cortisol is evident [<xref ref-type="bibr" rid="B40">40</xref>]. Stress hormones can also increase IL-18 synthesis at least in the layers of zona reticularis and zona fasciculate in the adrenal glands and peripheral mononuclear cells [<xref ref-type="bibr" rid="B40">40</xref>]. IL-18 secretion can be inhibited, at least in dendritic cells, with the calcium-channel blocker nifedipine [<xref ref-type="bibr" rid="B41">41</xref>].</p><p>APP is an integral membrane glycoprotein with receptor-like structure [<xref ref-type="bibr" rid="B42">42</xref>,<xref ref-type="bibr" rid="B43">43</xref>], but its physiological functions, and those of its cleavage products, are still to be fully clarified. Proliferating cells express APP, and it is detectable at the earliest stages of embryonic development [<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B45">45</xref>]. As described in Figure <xref ref-type="fig" rid="F1">1</xref>, the cleavage products of APP can be soluble N-terminal fragments APP&#x003b1; (sAPP&#x003b1;), APP&#x003b2; (sAPP&#x003b2;), as well as A&#x003b2; and different sized C-terminal fragments (CTFs), depending on whether APP is cleaved by &#x003b1;-, &#x003b2;-, or &#x003b3;-secretases, and the cleavage order [<xref ref-type="bibr" rid="B46">46</xref>]. In the amyloidogenic A&#x003b2;-producing pathway, APP is first cleaved by transmembrane protease &#x003b2;-site amyloid precursor protein-cleaving enzyme (BACE, &#x003b2;-secretase) [<xref ref-type="bibr" rid="B47">47</xref>], localized within Golgi, endosomes, and plasma membrane [<xref ref-type="bibr" rid="B48">48</xref>] and then by intramembrane &#x003b3;-secretase. &#x003b3;-secretase is a multiprotein complex containing a catalytic site harboring endoproteolytically cleaved N- and C-terminal fragments of presenilin-1 (PS-1), nicastrin, anterior pharynx defective 1 (Aph1), and presenilin enhancer 2 (Pen-2). This complex forms in the Golgi/trans-Golgi network [<xref ref-type="bibr" rid="B49">49</xref>]. In the non-amyloidogenic pathway, APP is cleaved by &#x003b1;-secretase. A Disintegrin and Metalloproteinase domain-containing proteins 9, 10, and 17 (ADAM9, ADAM10, ADAM17/TACE; TNF-&#x003b1; convertase) can function as an &#x003b1;-secretase [<xref ref-type="bibr" rid="B50">50</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Processing of APP by secretases.</bold> APP (85 kD) can be cleaved by &#x003b1;-secretase (&#x003b1;). This generates soluble APP&#x003b1; (sAPP&#x003b1;; 76 kD) and C-terminal fragment C83 (CTF&#x003b1;; ~9 kD). In the amyloidogenic pathway, APP is cleaved by &#x003b2;-secretase (&#x003b2;) to generate of sAPP&#x003b2; (74 kD) and the C-terminal fragment C99 (CTF&#x003b2;; approximately 11 kD), which in turn is cleaved by &#x003b3;-secretase (&#x003b3;) to generate amyloid-&#x003b2; (A&#x003b2;; approximately 4.5 kD) and amyloid intracellular domain AICD (CTF&#x003b3;; approximately 6 kD). AICD is also produced when C83 is cleaved by &#x003b3;-secretase [<xref ref-type="bibr" rid="B46">46</xref>]. This cleavage generates also P3 (approximately 2.6 kD). The N-terminal fragment of sAPP&#x003b2; can be cleaved by an as yet unconfirmed protease as N-APP (approximately 30 kD) and sAPP55 (approximately 45 kD) [<xref ref-type="bibr" rid="B51">51</xref>]. Arrowheads indicate caspase-3 cleavage site of APP amino acids (aa) [<xref ref-type="bibr" rid="B52">52</xref>]. WO-2 and 22C11 are used in this study as antibodies (ab) to detect the shown fragments. The dotted line pentagons indicate the binding sites of the antibodies.</p></caption><graphic xlink:href="1742-2094-9-199-1"/></fig><p>The amyloidogenic processing of APP seems to be at least partially regulated by its Thr668 phosphorylation (numbering for APP695 isoform) [<xref ref-type="bibr" rid="B53">53</xref>,<xref ref-type="bibr" rid="B54">54</xref>], including by the cyclin-dependent kinase 5 (Cdk5)/p35 complex [<xref ref-type="bibr" rid="B55">55</xref>]. Previously we showed that IL-18 increases not only protein levels of Cdk5/p35 but also glycogen synthase kinase-3&#x003b2; (GSK-3&#x003b2;) [<xref ref-type="bibr" rid="B19">19</xref>]. GSK-3&#x003b2; seems to be regulated at least partially by the Fe65/AICD complex [<xref ref-type="bibr" rid="B56">56</xref>]. GSK-3&#x003b2; phosphorylates and regulates the levels and function of PS-1 [<xref ref-type="bibr" rid="B57">57</xref>,<xref ref-type="bibr" rid="B58">58</xref>].</p><p>In this study, we examined the relationship of IL-18 on APP processing and A&#x003b2; formation <italic>in vitro</italic> in neuron-like differentiated SH-SY5Y-neuroblastoma cells. We found that IL-18 increased production of APP and its phosphorylation at Thr668. Further, IL-18 increased the amyloidogenic processing of APP by increasing expression of BACE-1 (70 kD) and levels of the 34 kD N-terminal fragment of PS-1 (NTF), contributing to a functional &#x003b3;-secretase. Expression of ADAM10 was very low in these cells, thus definite conclusions as to the impact of IL-18 cannot be made. Increased A&#x003b2; production after IL-18 administration was detectable in cell lysate, and this was prevented by the simultaneous application of IL-18 binding protein (IL-18&#x02009;bp). Increased A&#x003b2; production was also detectable in normal human astrocytes (NHA) after the addition of IL-18. IL-18 increased cellular level of bcl-xL but had only a minor impact on cellular caspase-3 and did not affect lactate dehydrogenase (LDH) activity in culture medium. Some comparison studies were done with IL-1&#x003b2;, and the results were somewhat in line with the IL-18 results, although the timeframe of changes seemed to be different.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Cell culture</title><p>The work was done with commercially available cells and products only. SH-SY5Y neuroblastoma (DSMZ; Braunschweig, Germany) were maintained in 50% Dulbecco&#x02019;s medium (DMEM; BioWhittaker/Lonza) containing 4.5&#x02009;g/L glucose and 50% Opti-MEM&#x000ae; Reduced Serum Medium with GlutaMAX&#x02122; (Invitrogen). Mixture was supplemented with 5% heat-inactivated fetal bovine serum (iFBS; HyClone/Pierce; Logan, UT, USA), 1&#x02009;mM&#x02009;L-glutamine (Lonza), 100 U/mL penicillin and 10&#x02009;&#x003bc;g/mL streptomycin (Lonza). The cells were plated as 10<sup>5</sup> cells/well into the 12-well plates (Nunc&#x02122;; Roskilde, Denmark) in DMEM containing the supplements. The cells were differentiated for 3&#x02009;days with 10&#x02009;&#x003bc;M all-trans retinoic acid (ATRA; Sigma-Aldrich; St Louis, MO, USA) treatment, which was followed by 4&#x02009;days of 50&#x02009;ng/mL human recombinant brain-derived neurotrophic factor (BDNF; Alomone Labs, Jerusalem, Israel) treatment in DMEM with supplements but without iFBS. Normal human astrocytes (NHA; Lonza) were plated as 6&#x02009;&#x000d7;&#x02009;10<sup>4</sup> cells/well in 12-well plates and they were grown in DMEM containing 4.5&#x02009;g/L glucose, and supplemented with 10% iFBS, 2&#x02009;mM&#x02009;L-glutamine, antibiotics, and 1&#x000d7; AGM<sup>TM</sup> SingleQuots&#x000ae; (Lonza). The NHA experiments were initiated 2&#x02009;days after plating.</p></sec><sec><title>Treatments</title><p>Recombinant human IL-18 (IL-18; MBL, Naka-ku Nagoya, Japan) was added to the culture medium as described [<xref ref-type="bibr" rid="B19">19</xref>]. IL-18 binding protein (IL-18&#x02009;bp; Recombinant Human IL-18BPa/Fc Chimera; R&#x00026;D Systems) was added at 0.5&#x02009;&#x003bc;g/mL to the pre-made IL-18 (100&#x02009;ng/mL) medium, and the mixture was added immediately to the cultures. BDNF was present in SH-SY5Y cultures during the IL-18 treatments. IL-1&#x003b2; (Biosource/Invitrogen) was used at 10, 20, 50, 100, 150&#x02009;ng/mL in some comparison SH-SY5Y experiments. NHA cells were treated with 100&#x02009;ng/mL IL-18, IL-1&#x003b2; (Biosource/Invitrogen), or Interferon-&#x003b3; (Biosource/Invitrogen) for 6&#x02009;h or exposed to 1&#x02009;mM H<sub>2</sub>O<sub>2</sub> (J.T.Baker; Deventer, Holland) in DMEM for 10&#x02009;min, after which fresh culture medium was added for 6&#x02009;h. Treatments were done without iFBS and AGM<sup>TM</sup> SingleQuots&#x000ae; supplementation. Amyloid &#x003b2;-Protein (1&#x02013;42) was purchased from Bachem (Bachem AG, Bubendorf, Switzerland). Some of the SH-SY5Y experiments were photographed just before harvesting by using Nikon Ecclipse TE300 inverted tissue culture microscope (objective Plan Fluor 20&#x000d7;/0.45) and Nikon Coolpix 995 camera. After the incubations, culture media were collected and the cells were lysed with M-PER lysis buffer (Pierce/Thermo Fisher Scientific Inc., Rockford, IL, USA) containing Protease Inhibitor Mix (GE Healthcare).</p></sec><sec><title>Protein, LDH, and ELISA measurements</title><p>Protein levels were estimated with the DC protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA) according to manufacturer&#x02019;s protocol. LDH activity was measured from SH-SY5Y culture medium with CytoTox 96&#x000ae; Nonradioactive Cytotoxicity Assay (Promega). A&#x003b2; forms were examined from cell lysate and culture medium by using Amyloid Beta x-40 and Amyloid Beta x-42 Chemiluminescent ELISA kits (Covance/Nordic Biosite) according to manufacturer&#x02019;s instructions.</p></sec><sec><title>Immunoblotting</title><p>Equal protein amounts (20&#x02009;&#x003bc;g or 35&#x02009;&#x003bc;g) from lysate and equal medium volumes (65 &#x003bc;L) were separated in 12.5% gels in sodium dodecyl sulfate polyacrylamide gel electrophoresis and the proteins were transferred to a Hybond P membrane (GE Healthcare). Full-Range and Low-Range Rainbow Molecular Weight Markers (GE Healthcare) as well as Novex&#x000ae; Sharp Prestained Protein Standard (Life Technologies&#x02122;) were used for the detection of the correct molecular weight targets.</p><p>The following antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA): BACE-1 (61-3E7; sc-33711), PS-1 (H-70; sc-7860), Pen-2 (FL-101; sc-32946), Aph-1 (H-50; sc-98469), nicastrin (N-19; sc-14369), ADAM10 (S-10; sc-16523), Fe65 (H-260; sc-33155), p-&#x003b2;-Amyloid (Thr 668) (sc-101632), caspase-3 p11 (K-19; sc-1224), and bcl-xL (S-18; sc-634). Anti-A&#x003b2;[<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B10">10</xref>]-Antibody (WO-2) was purchased from the Genetics Company, Inc. (Schlieren, Switzerland) and anti-Alzheimer precursor protein A4 antibody (22C11) from Chemicon/Millipore. Anti-Actin (H-196; sc-7210; Santa Cruz Biotechnology, Inc.) and anti-&#x003b1;-Tubulin (clone B-5-1-2, mouse Ascites fluid; Sigma-Aldrich) were used as loading controls.</p><p>The membranes were blocked with 3% non-fat milk (Valio; Finland) in phosphate buffered saline (PBS; pH 7.5)/0.05% Tween-20 (Sigma-Aldrich) for 1&#x02009;h, and the antibodies purchased from Santa Cruz Biotechnology, Inc. were used as 1:300 or 1:400 dilutions and Tubulin as 1:8000 as described [<xref ref-type="bibr" rid="B19">19</xref>]. When 22C11 and WO-2 antibodies were used, the membranes were blocked with 5% non-fat milk and 0.25% bovine serum albumin, fraction V (Roche Diagnostics; Mannheim, Germany) in Tris-buffered saline (pH 7.6; TBS)/0.05% Tween-20, at room temperature for 30&#x02009;min, after which the antibody (0.75&#x02009;&#x003bc;g/mL) was added. Incubations were done overnight at +4&#x02009;&#x000b0;C. After all antibody incubations, the membranes were washed as described [<xref ref-type="bibr" rid="B19">19</xref>].</p><p>For detection, the membranes were incubated with ECL&#x02122; donkey anti-rabbit IgG F(ab&#x02019;)<sub>2</sub> peroxidase-linked detection antibody (GE Healthcare), ECL&#x02122; anti-mouse IgG peroxidase-linked species-specific whole antibody (from sheep) (GE Healthcare) or bovine anti-goat IgG-HRP, mouse/human adsorbed (sc-2384; Santa Cruz Biotech.) detection antibodies at room temperature for 1 to 1.5&#x02009;h. Immobilon Western Chemiluminescent HRP Substrate (Millipore; Billerica, MA, USA) was added to the washed membrane and Fujifilm Super RX (Fuji Photo Film Co., Ltd) was used for the documentation. The detected bands were quantitied with a MCID M5-image analysis system (Imaging Research Inc.; Ontario, Canada).</p><p>The membranes were stripped after the detection by washing four times with TBS/0.1% Tween-20, incubating in stripping buffer (62.7&#x02009;mM Tris, 2% SDS and 0.7% &#x003b2;-mercaptoethanol; pH 6.8) slightly shaking at +50&#x02009;&#x000b0;C, followed by washing six times with TBS/0.1% Tween-20. The membranes were used three to five times.</p></sec><sec><title>Statistical analysis</title><p>The numerical results were analyzed with Mann&#x02013;Whitney <italic>U</italic>-Test (M-W) and Student&#x02019;s <italic>t</italic>-Test (<italic>t</italic>-Test). The experiments were independently repeated as indicated and the number (<italic>n</italic>) of controls and treatments were equal.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>IL-18 treatment increased protein levels of BACE-1, NTF of PS-1, and Fe65</title><p>First we examined the presence of IL-18 receptor (IL-18R) and IL-18&#x02009;bp in differentiated SH-SY5Y neuroblastoma cells. Our cells expressed IL-18R and its protein levels were unaltered by IL-18 treatments (data not shown). IL-18&#x02009;bp was not detectable at the protein level (data not shown). We also detected added correct size IL-18 in the cell lysate even in 72-h treated cells indicating its stability (Figure <xref ref-type="fig" rid="F2">2</xref>H). Our findings are in line with Sallmon <italic>et al</italic>. (2010), who have previously shown that SH-SY5Y neuroblastoma cells express IL-18R and IL-18&#x02009;bp, and when differentiated with ATRA, also IL-18, whereas the level of IL-18&#x02009;bp reduces after ATRA treatment [<xref ref-type="bibr" rid="B59">59</xref>].</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Levels of APP cleaving enzymes in neuron-like differentiated SH-SY5Y neuroblastoma cells.</bold> The cells were treated with IL-18 (50, 100, or 150&#x02009;ng/mL) for described times. (<bold>A</bold>) BACE-1 (70 kD) increased after 100&#x02009;ng/mL IL-18 treatment compared to the untreated control (a), (b); the impact of IL-18 was suppressed with IL-18&#x02009;bp (IL-18 100&#x02009;ng/mL&#x02009;+&#x02009;IL-18BPa 0.5&#x02009;&#x003bc;g/mL) (b). (<bold>B</bold>) IL-18, in a concentration-dependent manner, increased protein level of NTF of PS-1 (34 kD) compared to the untreated control. Protein synthesis of PS-1 (53 kD) increased slightly only at 24&#x02009;h in IL-18 treated cells. The bands above are likely partially formed &#x003b3;-secretase complexes including NTF of PS-1. (<bold>C</bold>) IL-18 treatment increased expression of Pen-2 at 72&#x02009;h. Arrowheads indicate bands in PS-1 and Pen-2 films co-localized when the Pen-2 and PS-1 films were superimposed. (<bold>D</bold>) Fe65 (77 kD) increased in 24-h treated cells. (<bold>E</bold>) Loading control actin for the results B to D, which were obtained from the same membrane. (<bold>F</bold>) Aph-1 (29 kD) and nicastrin increased in 24-h IL-18 treated cells. The probings are from the same membrane and arranged according to the superimposing. (<bold>G</bold>) Expression of ADAM10 was generally very low (60 kD active form, 80 kD partially processed, 100 kD precursor). (<bold>H</bold>) The presence of recombinant IL-18 in 72-h IL-18 treated SH-SY5Y lysate. Actin and Tubulin were used as loading references. Ctrl, untreated control; NTF, N-terminal fragment of PS-1; RcIL-18, recombinant IL-18.</p></caption><graphic xlink:href="1742-2094-9-199-2"/></fig><p>We examined how IL-18 affects protein levels of particularly BACE-1 and PS-1 in neuron-like differentiated SH-SY5Y neuroblastoma. IL-18 (100&#x02009;ng/mL) increased the protein levels of BACE-1 (70 kD) at 24&#x02009;h (131%, <italic>P</italic> &#x0003c;0.000) and 72&#x02009;h (68%, <italic>P</italic> &#x0003c;0.000) time points (Figure <xref ref-type="fig" rid="F2">2</xref>A(a),(b); Table <xref ref-type="table" rid="T1">1</xref>), and the impact of IL-18 was suppressed with simultaneous treatment with 0.5&#x02009;&#x003bc;g/mL IL-18&#x02009;bp (Figure <xref ref-type="fig" rid="F2">2</xref>A(b), last lane). The effect of IL-18 on BACE-1 was also concentration (50&#x02013;150&#x02009;ng/mL) dependent particularly in 24-h treated cells (data not shown). Protein levels of NTF of PS-1 (34 kD) were also increased by IL-18 in a concentration dependent manner (50&#x02013;150&#x02009;ng/mL) (Figure <xref ref-type="fig" rid="F2">2</xref>B). The increase in NTF was significant at 6&#x02009;h in IL-18 treated cells (192%, <italic>P</italic> 0.017) (Table <xref ref-type="table" rid="T1">1</xref>). The 53 kD precursor of PS-1 was significantly increased later, at 48&#x02009;h, following IL-18 addition (26%, <italic>P</italic> 0.068 (M-W), <italic>P</italic> 0.050 (<italic>t</italic>-Test)) (Table <xref ref-type="table" rid="T1">1</xref>) with the increase at 24&#x02009;h approaching significance (67%, <italic>P</italic> 0.058 (<italic>t</italic>-Test)) (Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Mean percentage alteration of protein levels of IL-18 treated targets compared to untreated ones, analyzed from western blots</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="right"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left">&#x000a0;</th><th align="right">&#x000a0;</th><th align="center"><bold>6&#x02009;h</bold></th><th align="center"><bold>24&#x02009;h</bold></th><th align="center"><bold>48&#x02009;h</bold></th><th align="center"><bold>72&#x02009;h</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">APP, approximately&#x02009;&#x02009;100 kD<hr/></td><td align="right" valign="bottom">Mean %&#x02009;&#x000b1;&#x02009;SEM<hr/></td><td align="center" valign="bottom"><bold>74.9</bold> &#x000b1;17.2<hr/></td><td align="center" valign="bottom"><bold>19.3</bold> &#x000b1;9.9<hr/></td><td align="center" valign="bottom"><bold>56.5</bold> &#x000b1;12.4<hr/></td><td align="center" valign="bottom"><bold>&#x02212;3.0</bold> &#x000b1;10.1<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="right" valign="bottom"><italic>n</italic><hr/></td><td align="center" valign="bottom">20<hr/></td><td align="center" valign="bottom">31<hr/></td><td align="center" valign="bottom">30<hr/></td><td align="center" valign="bottom">31<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="right" valign="bottom"><italic>t</italic>-Test, <italic>P</italic><hr/></td><td align="center" valign="bottom"><bold><italic>&#x0003c;0.000</italic></bold><sup>a</sup><hr/></td><td align="center" valign="bottom"><italic>0.062</italic><hr/></td><td align="center" valign="bottom"><bold><italic>&#x0003c;0.000</italic></bold><sup>a</sup><hr/></td><td align="center" valign="bottom"><italic>0.769</italic><hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="right" valign="bottom">M-W, <italic>P</italic><hr/></td><td align="center" valign="bottom"><bold><italic>0.001</italic></bold><sup>a</sup><hr/></td><td align="center" valign="bottom"><italic>0.809</italic><hr/></td><td align="center" valign="bottom"><bold><italic>&#x0003c;0.000</italic></bold><sup>a</sup><hr/></td><td align="center" valign="bottom"><italic>0.243</italic><hr/></td></tr><tr><td align="left" valign="bottom">BACE-1, approximately 70 kD<hr/></td><td align="right" valign="bottom">Mean %&#x02009;&#x000b1;&#x02009;SEM<hr/></td><td align="center" valign="bottom"><bold>35.1</bold> &#x000b1;29.7<hr/></td><td align="center" valign="bottom"><bold>131.1</bold> &#x000b1;35.4<hr/></td><td align="center" valign="bottom"><bold>39.1</bold> &#x000b1;25.1<hr/></td><td align="center" valign="bottom"><bold>67.8</bold> &#x000b1;21.5<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="right" valign="bottom"><italic>N</italic><hr/></td><td align="center" valign="bottom">11<hr/></td><td align="center" valign="bottom">20<hr/></td><td align="center" valign="bottom">18<hr/></td><td align="center" valign="bottom">19<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="right" valign="bottom"><italic>t</italic>-Test, <italic>P</italic><hr/></td><td align="center" valign="bottom"><italic>0.107</italic><hr/></td><td align="center" valign="bottom"><bold><italic>0.002</italic></bold><sup>b</sup><hr/></td><td align="center" valign="bottom"><italic>0.310</italic><hr/></td><td align="center" valign="bottom"><bold><italic>0.006</italic></bold><sup>b</sup><hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="right" valign="bottom">M-W, <italic>P</italic><hr/></td><td align="center" valign="bottom"><italic>0.700</italic><hr/></td><td align="center" valign="bottom"><bold><italic>&#x0003c;0.000</italic></bold><sup>a</sup><hr/></td><td align="center" valign="bottom"><italic>0.543</italic><hr/></td><td align="center" valign="bottom"><bold><italic>&#x0003c;0.000</italic></bold><sup>a</sup><hr/></td></tr><tr><td align="left" valign="bottom">PS-1, approximately 34 kD<hr/></td><td align="right" valign="bottom">Mean %&#x02009;&#x000b1;&#x02009;SEM<hr/></td><td align="center" valign="bottom"><bold>191.9</bold> &#x000b1;80.7<hr/></td><td align="center" valign="bottom"><bold>22.6</bold> &#x000b1;28.4<hr/></td><td align="center" valign="bottom"><bold>26.5</bold> &#x000b1;25.9<hr/></td><td align="center" valign="bottom"><bold>5.4</bold> &#x000b1;16.0<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="right" valign="bottom"><italic>n</italic><hr/></td><td align="center" valign="bottom">7<hr/></td><td align="center" valign="bottom">17<hr/></td><td align="center" valign="bottom">16<hr/></td><td align="center" valign="bottom">18<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="right" valign="bottom"><italic>t</italic>-Test, <italic>P</italic><hr/></td><td align="center" valign="bottom"><italic>0.055</italic><hr/></td><td align="center" valign="bottom"><italic>0.322</italic><hr/></td><td align="center" valign="bottom"><italic>0.323</italic><hr/></td><td align="center" valign="bottom"><italic>0.741</italic><hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="right" valign="bottom">M-W, <italic>P</italic><hr/></td><td align="center" valign="bottom"><bold><italic>0.017</italic></bold><sup>c</sup><hr/></td><td align="center" valign="bottom"><italic>0.734</italic><hr/></td><td align="center" valign="bottom"><italic>0.519</italic><hr/></td><td align="center" valign="bottom"><italic>1.000</italic><hr/></td></tr><tr><td align="left" valign="bottom">PS-1, approximately 53 kD<hr/></td><td align="right" valign="bottom">Mean %&#x02009;&#x000b1;&#x02009;SEM<hr/></td><td align="center" valign="bottom"><bold>121.9</bold> &#x000b1;68.7<hr/></td><td align="center" valign="bottom"><bold>67.0</bold> &#x000b1;32.9<hr/></td><td align="center" valign="bottom"><bold>26.0</bold> &#x000b1;12.3<hr/></td><td align="center" valign="bottom"><bold>&#x02212;18.9</bold> &#x000b1;10.4<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="right" valign="bottom"><italic>n</italic><hr/></td><td align="center" valign="bottom">9<hr/></td><td align="center" valign="bottom">18<hr/></td><td align="center" valign="bottom">18<hr/></td><td align="center" valign="bottom">18<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="right" valign="bottom"><italic>t</italic>-Test, <italic>P</italic><hr/></td><td align="center" valign="bottom"><italic>0.114</italic><hr/></td><td align="center" valign="bottom"><italic>0.058</italic><hr/></td><td align="center" valign="bottom"><bold><italic>0.050</italic></bold>c<hr/></td><td align="center" valign="bottom"><italic>0.087</italic><hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="right" valign="bottom">M-W, <italic>P</italic><hr/></td><td align="center" valign="bottom"><italic>0.203</italic><hr/></td><td align="center" valign="bottom"><italic>0.543</italic><hr/></td><td align="center" valign="bottom"><italic>0.068</italic><hr/></td><td align="center" valign="bottom"><italic>0.543</italic><hr/></td></tr><tr><td align="left" valign="bottom">PS-1, approximately 100 kD<hr/></td><td align="right" valign="bottom">Mean %&#x02009;&#x000b1;&#x02009;SEM<hr/></td><td align="center" valign="bottom"><bold>79.7</bold> &#x000b1;55.9<hr/></td><td align="center" valign="bottom"><bold>51.4</bold> &#x000b1;19.2<hr/></td><td align="center" valign="bottom"><bold>27.8</bold> &#x000b1;16.4<hr/></td><td align="center" valign="bottom"><bold>8.1</bold> &#x000b1;12.1<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="right" valign="bottom"><italic>n</italic><hr/></td><td align="center" valign="bottom">10<hr/></td><td align="center" valign="bottom">19<hr/></td><td align="center" valign="bottom">19<hr/></td><td align="center" valign="bottom">20<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="right" valign="bottom"><italic>t</italic>-Test, <italic>P</italic><hr/></td><td align="center" valign="bottom"><italic>0.106</italic><hr/></td><td align="center" valign="bottom"><italic>0.138</italic><hr/></td><td align="center" valign="bottom"><italic>0.767</italic><hr/></td><td align="center" valign="bottom"><italic>0.247</italic><hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="right" valign="bottom">M-W, <italic>P</italic><hr/></td><td align="center" valign="bottom"><italic>0.192</italic><hr/></td><td align="center" valign="bottom"><bold><italic>0.016</italic></bold><sup>c</sup><hr/></td><td align="center" valign="bottom"><italic>0.106</italic><hr/></td><td align="center" valign="bottom"><italic>0.377</italic><hr/></td></tr><tr><td align="left" valign="bottom">bcl-xL, approximately 30 kD<hr/></td><td align="right" valign="bottom">Mean %&#x02009;&#x000b1;&#x02009;SEM<hr/></td><td align="center" valign="bottom"><bold>20.7</bold> &#x000b1;36.6<hr/></td><td align="center" valign="bottom"><bold>&#x02212;6.3</bold> &#x000b1;11.2<hr/></td><td align="center" valign="bottom"><bold>17.7</bold> &#x000b1;19.5<hr/></td><td align="center" valign="bottom"><bold>23.5</bold> &#x000b1;8.7<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="right" valign="bottom"><italic>n</italic><hr/></td><td align="center" valign="bottom">5<hr/></td><td align="center" valign="bottom">15<hr/></td><td align="center" valign="bottom">14<hr/></td><td align="center" valign="bottom">14<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="right" valign="bottom"><italic>t</italic>-Test, <italic>P</italic><hr/></td><td align="center" valign="bottom"><italic>0.602</italic><hr/></td><td align="center" valign="bottom"><italic>0.582</italic><hr/></td><td align="center" valign="bottom"><italic>0.381</italic><hr/></td><td align="center" valign="bottom"><bold><italic>0.018</italic></bold><sup>c</sup><hr/></td></tr><tr><td align="left">&#x000a0;</td><td align="right">M-W, P</td><td align="center"><italic>0.577</italic></td><td align="center"><italic>0.319</italic></td><td align="center"><bold><italic>0.034</italic></bold><sup>c</sup></td><td align="center"><bold><italic>0.039</italic></bold><sup>c</sup></td></tr></tbody></table><table-wrap-foot><p>SEM, Standard error of mean; <italic>n</italic>, number of repeats; <italic>t</italic>-Test, Student&#x02019;s <italic>t</italic>-Test; M-W, Mann&#x02013;Whitney <italic>U</italic>-Test; <italic>P</italic>, <italic>P</italic> value.</p><p><sup>a</sup><italic>P</italic> value, 0.001.</p><p><sup>b</sup><italic>P</italic> value, 0.01.</p><p><sup>c</sup><italic>P</italic> value, 0.05.</p></table-wrap-foot></table-wrap><p>Since Pen-2 is required for the endocytic processing of PS-1 (53 kD) and activation of the &#x003b3;-secretase complex [<xref ref-type="bibr" rid="B60">60</xref>], we investigated its protein levels following IL-18 addition. Pen-2 interacts with NTF but not with CTF of PS-1 [<xref ref-type="bibr" rid="B61">61</xref>]. However, Pen-2 (12 kD) was generally hardly detectable in most of the experiments (<italic>n</italic>&#x02009;=&#x02009;9) at the 12 kD band, but at the highest concentration used (150&#x02009;ng/mL) IL-18 appeared to increase its protein level at 72&#x02009;h (Figure <xref ref-type="fig" rid="F2">2</xref>C). However, increased levels of Pen-2 antibody reactivity was found around the 80 kD band in IL-18 treated cells (Figure <xref ref-type="fig" rid="F2">2</xref>C,F). Aph1 and Nicastrin showed also some increase in 24-h IL-18 treated cells (Figure <xref ref-type="fig" rid="F2">2</xref>&#x02009;F). Nevertheless, since the active &#x003b3;-secretase complex includes the NTF and CTF (18.5 kD) of PS-1, Pen-2 (interacts with NTF), Aph1 (29 kD; interacts with CTF) and nicastrin (75 kD as unglycosylated), the high molecular weight bands shown in Figure <xref ref-type="fig" rid="F2">2</xref>B, C, and F are likely partially formed &#x003b3;-secretase complexes. The approximate 100 kD band cluster (Figure <xref ref-type="fig" rid="F2">2</xref>B) was measured and its increase was 51% (<italic>P</italic> 0.016 (<italic>t</italic>-Test)) (Table <xref ref-type="table" rid="T1">1</xref>) at 24&#x02009;h after the IL-18 treatments.</p><p>Due to our earlier findings with GSK-3&#x003b2; [<xref ref-type="bibr" rid="B19">19</xref>], we also examined protein levels of Fe65. Fe65 (77 kD) interacts with AICD (Figure <xref ref-type="fig" rid="F1">1</xref>) and this complex regulates expression of GSK-3&#x003b2; [<xref ref-type="bibr" rid="B56">56</xref>], which in turn can regulate for instance the levels and function of PS-1 [<xref ref-type="bibr" rid="B57">57</xref>,<xref ref-type="bibr" rid="B58">58</xref>]. Protein levels of Fe65 were increased at 24&#x02009;h in IL-18 treated cells, at IL-18 concentrations of 100 or 150&#x02009;ng/mL (Figure <xref ref-type="fig" rid="F2">2</xref>D).</p><p>Expression of ADAM10, one of the &#x003b1;-secretases, was very low in our cells (Figure <xref ref-type="fig" rid="F2">2</xref>G) suggesting that it is not the main &#x003b1;-secretase in SH-SY5Y cells. Other &#x003b1;-secretases were not examined. However, it seemed that IL-18 treatment slightly decreased the 60 kD active form of ADAM10 levels when compared to actin (Figure <xref ref-type="fig" rid="F2">2</xref>G), but this result requires confirmation with other methods.</p></sec><sec><title>IL-18 treatment increased levels of APP, altered its processing, and increased A&#x003b2; levels in SH-SY5Y cells</title><p>IL-18 increased protein level of APP (75%, <italic>P</italic> 0.001) (Figure <xref ref-type="fig" rid="F3">3</xref>A, Table <xref ref-type="table" rid="T1">1</xref>) as well as its phosphorylation at the Thr668 site (Figure <xref ref-type="fig" rid="F3">3</xref>B) in 6-h treated SH-SY5Y cells. Increase of APP was detectable also at the 48-h time-point (57%, <italic>P</italic> &#x0003c;0.000) (Table <xref ref-type="table" rid="T1">1</xref>).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Expression of APP products in differentiated SH-SY5Y neuroblastoma cells and in normal human astrocytes.</bold> The differentiated SH-SY5Y-cells were treated with IL-18 (100&#x02009;ng/mL) without or with IL-18&#x02009;bp (0.5&#x02009;&#x003bc;g/mL) for described times. IL-18 treatment increased (<bold>A</bold>) APP synthesis during 6-h and 48-h treatment and (<bold>B</bold>) Thr668 phosphorylation of APP during 6-h treatment in SH-SY5Y cells. IL-18 treatment also increased the protein levels of (<bold>C</bold>) C99 (approximately 11 kD) and A&#x003b2; (approximately 4 kD) (WO-2 antibody), the BACE-1 and &#x003b3;-secretase cleavage products of APP in (a) differentiated SH-SY5Y cells but also in (b) normal human astrocytes. When examined from the same SH-SY5Y culture medium, (<bold>D</bold>) total sAPP was only slightly increased by the IL-18 treatment (22C11 antibody detects sAPP&#x003b1; (76 kD) and sAPP&#x003b2; (74 kD)). When WO-2 antibody was used (detects only sAPP&#x003b1;) for the same samples, the protein level of sAPP&#x003b1; was less in IL-18 treated culture medium, compared to untreated control (Ctrl), showing indirectly the increase in sAPP&#x003b2; production by IL-18 in SH-SY5Y medium.</p></caption><graphic xlink:href="1742-2094-9-199-3"/></fig><p>As detected by WO-2 antibody from the SH-SY5Y lysate, 100&#x02009;ng/mL IL-18, for 24 or 72&#x02009;h, increased the protein levels of APP cleavage products: A&#x003b2; (approximately 4 kD) and C99 (approximately 11 kD), as well as faintly expressed bands at approximately 76 kD (possibly sAPP&#x003b1;) and approximately 46 kD (possibly sAPP cleavage product (Figure <xref ref-type="fig" rid="F1">1</xref>)) as shown in Figure <xref ref-type="fig" rid="F3">3</xref>C(a). The effect of IL-18 was abolished with simultaneous treatment with 0.5&#x02009;&#x003bc;g/mL of IL-18bpA (Figure <xref ref-type="fig" rid="F3">3</xref>C(a)), which is the predominant IL-18&#x02009;bp form. Interestingly, IL-18 also increased levels of C99 and A&#x003b2; in NHA-cells treated for 6&#x02009;h. IFN-&#x003b3; (100&#x02009;ng/mL) and 1&#x02009;mM H<sub>2</sub>O<sub>2</sub> (10&#x02009;min insult) had a similar effect, whereas IL-1&#x003b2; had no impact (Figure <xref ref-type="fig" rid="F3">3</xref>C(b)). Nevertheless, in both cell types, the produced type of A&#x003b2; was mainly A&#x003b2;40 although some A&#x003b2;42 was also produced (ratio: approximately 3 A&#x003b2;42/100 A&#x003b2;40). The total amount of A&#x003b2;40 (cell lysate and medium) was approximately 260.7&#x02009;pg in 10<sup>5</sup> SH-SY5Y cells, treated with IL-18 for 72&#x02009;h <italic>vs.</italic> approximately 229.9&#x02009;pg in 10<sup>5</sup> untreated cells (13.3%, SEM &#x000b1;0.81; <italic>n</italic>&#x02009;=&#x02009;3; <italic>P</italic> 0.004 (<italic>t</italic>-Test)). However, the A&#x003b2;40 estimate is very crude, due to the pronounced background in ELISA. A&#x003b2;42 levels were estimated to be approximately 7.14&#x02009;pg/mL from the same samples, but no clear difference between IL-18 treatment and control were apparent partially due to the sensitivity limits of the ELISA kit.</p><p>In SH-SY5Y culture medium, the ratio of sAPP&#x003b1; and sAPP&#x003b2; showed alteration during the IL-18 treatment when compared to the untreated control (Figure <xref ref-type="fig" rid="F3">3</xref>D). As indirectly shown (binding regions for the antibodies are shown in Figure <xref ref-type="fig" rid="F1">1</xref>), IL-18 treatment increased the proportion of sAPP&#x003b2; from total sAPP, whereas in untreated control cell medium, the amount of sAPP&#x003b1; was greater, supporting the increased &#x003b2;-amyloidogenic processing of APP.</p></sec><sec><title>IL-1&#x003b2; altered the expression levels of BACE-1, PS-1 and APP but differently to IL-18</title><p>We treated differentiated SH-SY5Y cells also with IL-1&#x003b2; (10- to 150&#x02009;ng/mL) as reference for IL-18. Since our main interest was IL-18, the number of repeats of these experiments was not enough to do proper statistics. However, changes were apparent mainly with 50&#x02009;ng/mL or 100&#x02009;ng/mL of IL-1&#x003b2; whereas 10 or 20&#x02009;ng/mL was too low for our targets and 150&#x02009;ng/mL seemed to be harmful to the cells. Nevertheless, the main increase of BACE-1 appeared later than with IL-18, at 48&#x02009;h when 50&#x02009;ng/mL of IL-1&#x003b2; was used (Figure <xref ref-type="fig" rid="F4">4</xref>A). The impacts of IL-1&#x003b2; on PS-1 were also less than that of IL-18 (Figure <xref ref-type="fig" rid="F4">4</xref>B). IL-1&#x003b2; treatment concentration dependently also increased APP levels during 6-h treatment (Figure <xref ref-type="fig" rid="F4">4</xref>C) and A&#x003b2; became apparent (Figure <xref ref-type="fig" rid="F4">4</xref>D) at 24&#x02009;h. Similar kind of results were gained when IL-1&#x003b2; was used as 100&#x02009;ng/mL. However, IL-1 is tightly regulated and we did not examine the expression levels for instance of IL-1 receptor (IL-1R), IL-1 receptor antagonist (IL-Ra), or IL-1 receptor accessory protein (IL-1RAcP). The low expression level of, for example, IL-1RI or IL-1RAcP may cause the poor response of SH-SY5Y to IL-1, whereas high expression of IL-1Ra or soluble IL-1RII, shed from the plasma membrane by BACE-1 [<xref ref-type="bibr" rid="B62">62</xref>], may inhibit IL-1 binding to its functional receptor and thus reducing the response of the cells.</p><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>IL-1&#x003b2; treated differentiated SH-SY5Y cells.</bold> The cells were treated with IL-1&#x003b2; (50, 100, or 150&#x02009;ng/ mL) for described times. (<bold>A</bold>) BACE-1 (70 kD) increased particularly in 48-hr IL-1&#x003b2; treatment (50&#x02009;ng/mL) compared to the untreated control. Actin was used as loading control. (<bold>B</bold>) IL-1&#x003b2; increased protein level of NTF of PS-1 (34 kD), whereas protein synthesis of precursor PS-1 (53 kD) decreased in 6-h or 24-h IL-1&#x003b2; treated cells compared to untreated control. (<bold>C</bold>) IL-1&#x003b2; treatment increased protein levels of APP concentration dependently in 6-h treated cells. (<bold>D</bold>) IL-1&#x003b2; treatment increased slightly A&#x003b2; production. (<bold>E</bold>) Bcl-xL reduced in 6-h IL-1&#x003b2; treated cells but increased in the final 72-h time point. Ctrl, untreated control; NTF, N-terminal fragment of PS-1.</p></caption><graphic xlink:href="1742-2094-9-199-4"/></fig></sec><sec><title>IL-18 treatment increased cellular level of bcl-xL but had only a minor impact on cellular caspase-3 and did not affect LDH activity in culture medium</title><p>Since IL-18 treatment increased A&#x003b2; levels in cell lysate, and binding of IL-18 to its receptor complex can lead to activation of JNK and MAPK p38 [<xref ref-type="bibr" rid="B63">63</xref>], in turn activating pro-apoptotic signaling pathways [<xref ref-type="bibr" rid="B64">64</xref>], we examined expression of pro-apoptotic caspase-3 and anti-apoptotic bcl-xL from the cell lysate as well as LDH activity from the culture medium.</p><p>Expression of pro-caspase-3 (32 kD) was reduced at 6&#x02009;h in IL-18 treated cells, but increased at 72&#x02009;h (Figure <xref ref-type="fig" rid="F5">5</xref>A). However, the protein level of caspase-3 (approximately 58 kD; approximate size of an active tetramer complex), showed only a minor increase at 72&#x02009;h (Figure <xref ref-type="fig" rid="F5">5</xref>A). IL-18 also increased bcl-xL levels at 72&#x02009;h (23%, <italic>P</italic> 0.039) (Table <xref ref-type="table" rid="T1">1</xref>) in a concentration dependent manner (Figure <xref ref-type="fig" rid="F5">5</xref>B). The activity of LDH was not altered in culture medium even when IL-18 was used at 100 or 150&#x02009;ng/mL for 72&#x02009;h with or without 1&#x02009;&#x003bc;M A&#x003b2;42 addition (data not shown). The survival of IL-18 or IL-1&#x003b2; treated with or without A&#x003b2;42 addition and untreated control cells showed no significant difference either, even after 72-h incubation (Figure <xref ref-type="fig" rid="F6">6</xref>) in all experiments (<italic>n</italic>&#x02009;=&#x02009;6). However, A&#x003b2;42 treatment caused clustering of the cells, particularly when IL-18 was included (Figure <xref ref-type="fig" rid="F6">6</xref>E). Further studies with longer incubation time will be required to test for the differences, including vacuolization.</p><fig id="F5" position="float"><label>Figure 5</label><caption><p><bold>Protein levels of indicators of apoptosis in differentiated SH-SY5Y cells.</bold> The cells were treated with IL-18 (100&#x02009;ng/mL) for described times. IL-18 (<bold>A</bold>) decreased pro-caspase-3 (approximately 32 kD) at 6&#x02009;h, but increased its level in 72-h treated cells. The approximate 58 kD form, which is likely the active form composed of two 12 and 17 kD fragments of caspase-3, increased very slightly in 72-h treated cells. (<bold>B</bold>) Bcl-xL, which inhibits activation of caspases, was slightly reduced at 6-h IL-18 treated cells but induced in 72-h timepoint. Actin was used as a loading control.</p></caption><graphic xlink:href="1742-2094-9-199-5"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><p><bold>The appearance of differentiated SH-SY5Y cells after IL-18 or IL-1&#x003b2; treatments with or without amyloid-&#x003b2;42 addition.</bold> (<bold>A</bold>) Differentiated untreated control cells. (<bold>B</bold>) The cells were treated with IL-18 (100&#x02009;ng/mL) or (<bold>C</bold>) with IL-1&#x003b2; (50&#x02009;ng/mL) for 72&#x02009;h. IL-1&#x003b2; exposed cells seemed to be more vacuolized than the control cells or IL-18 treated cells. The cells were treated (<bold>D</bold>) with 1&#x02009;&#x003bc;M A&#x003b2;42 only, (<bold>E</bold>) with IL-18 (100&#x02009;ng/mL), and 1&#x02009;&#x003bc;M A&#x003b2;42 for 72&#x02009;h, (<bold>F</bold>) with IL-1&#x003b2; (50&#x02009;ng/mL) and 1&#x02009;&#x003bc;M A&#x003b2;42 for 72&#x02009;h. The arrowheads indicate the clustering of the cells. Magnification 200x, bar 10&#x02009;&#x003bc;m as shown in (A).</p></caption><graphic xlink:href="1742-2094-9-199-6"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>We found that IL-18 can increase production of APP and its Thr668 phosphorylation in neuron-like differentiated human SH-SY5Y cells. IL-18 also increased amyloidogenic processing to A&#x003b2; by inducing expression of BACE-1 and NTF of PS-1, part of the functional &#x003b3;-secretase complex. IL-18 slightly increased protein levels of the anti-apoptotic bcl-xL and apoptotic caspase-3, but had no effect on LDH release.</p><p>The IL-18 increase in APP protein levels was an early response. APP, a member of the gene family including Amyloid Precursor-Like Proteins APLP1 and APLP2, exists as several distinct isoforms arising by alternative splicing of a single gene. The predominant neuronal APP isoform is APP695 [<xref ref-type="bibr" rid="B65">65</xref>]. APP has importance in cortical development, and mice that lack all three APP family members exhibit early postnatal lethality and neuroanatomical abnormalities [<xref ref-type="bibr" rid="B66">66</xref>]. APP may participate in regulation of the cell cycle during embryonic development [<xref ref-type="bibr" rid="B45">45</xref>], and seems required for correct neuronal migration [<xref ref-type="bibr" rid="B67">67</xref>]. APP forms are also associated with neurite outgrowth [<xref ref-type="bibr" rid="B68">68</xref>], with the cytoplasmic domain of APP interacting with the cytosolic adapter Fe65 in the regulation of neurite branching [<xref ref-type="bibr" rid="B69">69</xref>]. APP can also be rapidly transported down the axon to the synapses and, like A&#x003b2;, may have importance in the formation of synapses [<xref ref-type="bibr" rid="B70">70</xref>] and their functional regulation [<xref ref-type="bibr" rid="B71">71</xref>]. Thus, IL-18 may enhance neurite and synapse formation, which is in line with our earlier observations [<xref ref-type="bibr" rid="B19">19</xref>].</p><p>The IL-18 induced increase in APP Thr668 phosphorylation was an early response. APP has eight potential phosphorylation sites in its cytoplasmic domain [<xref ref-type="bibr" rid="B72">72</xref>], with its phosphorylation increasing in parallel with neuronal differentiation, especially at the time of neurite outgrowth [<xref ref-type="bibr" rid="B43">43</xref>]. Further, phosphorylated APP is distributed in neurites, particularly in growth cones [<xref ref-type="bibr" rid="B43">43</xref>]. Whereas GSK-3&#x003b2; can phosphorylate the cytoplasmic domain of the APP at its Thr743 [<xref ref-type="bibr" rid="B73">73</xref>], Cdk5, GSK-3&#x003b1;, and JNKs can mediate phosphorylation of N- and O-glycosylated APP at its Thr668 site [<xref ref-type="bibr" rid="B55">55</xref>,<xref ref-type="bibr" rid="B74">74</xref>]. Thr668 phosphorylation is linked to neurite extension and anterograde transport of vesicular cargo [<xref ref-type="bibr" rid="B75">75</xref>]. As such IL-18, via its modulation of APP, will impact on wide cellular processes, including synaptic plasticity. Further, Thr668 phosphorylation of APP facilitates its BACE-1 cleavage [<xref ref-type="bibr" rid="B54">54</xref>] aiding the initiation of the amyloidogenic pathway (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><p>IL-18 also increased protein levels of BACE-1 (approximately 70 kD). BACE-1 is essential for cognitive, emotional, and synaptic functions [<xref ref-type="bibr" rid="B76">76</xref>]. Electrophysiologically, BACE-1-deficient neurons exhibit subtle alterations in the steady-state inactivation of voltage-gated sodium channels [<xref ref-type="bibr" rid="B77">77</xref>]. BACE-1 knockout mice in turn displayed significant neonatal lethality, suggesting an essential function. BACE-1 is highly expressed at the time when peripheral nerves become myelinated and is needed for neuregulin processing, with loss of BACE-1 inducing hypomyelination [<xref ref-type="bibr" rid="B78">78</xref>], suggestive of a role for IL-18 and BACE-1 in multiple sclerosis [<xref ref-type="bibr" rid="B79">79</xref>]. Further, experimental traumatic brain injury in rats also stimulates BACE-1 expression, production, and activity [<xref ref-type="bibr" rid="B80">80</xref>]. Thus, increased expression of BACE-1 by IL-18 suggests that BACE-1 and A&#x003b2; may be needed for synapse formation and sodium-voltage gate regulation during development as well as during regeneration. The role of IL-18 in the regulation of hypomyelination in neurodegenerative disorders requires further investigation.</p><p>The impact of IL-18 on PS-1 was not as pronounced as on APP and BACE-1. IL-18 increased precursor PS-1 (53 kD) moderately as well as Pen-2 (12 kD) very slightly, but later than the increase in APP and its Thr668 phosphorylation. The levels of endoproteolytic NTF of PS-1 significantly increased approximately at the time of the rise in APP and BACE-1. This suggests that the immediate interaction of Pen-2 with the PS-1 precursor leads to the endoproteolytic cleavage of PS-1 and to the formation of a functional &#x003b3;-secretase complex. Despite this, in our experiments, the limiting factor for A&#x003b2; production seemed to be &#x003b3;-secretase, since the level of C99 fragment (Figure <xref ref-type="fig" rid="F1">1</xref>) was generally higher than that of A&#x003b2; indicating the need of an additional stimulus for activation of &#x003b3;-secretase. It has been shown that absence of PS-1 and PS-1/PS-2 strongly reduces Pen-2, which is further reduced when nicastrin level is low [<xref ref-type="bibr" rid="B81">81</xref>]. On the other hand, down-regulation of Pen-2 decreased PS levels and impaired nicastrin maturation, resulting in deficient &#x003b3;-secretase complex formation. Thus the components of the &#x003b3;-secretase complex are expressed in a coordinated manner [<xref ref-type="bibr" rid="B81">81</xref>]. Nevertheless, &#x003b3;-secretase has an essential role in development and neurogenesis [<xref ref-type="bibr" rid="B82">82</xref>,<xref ref-type="bibr" rid="B83">83</xref>], but it is also a promiscuous aspartyl protease, which can cleave numerous type-I transmembrane proteins after their large ectodomain are shed [<xref ref-type="bibr" rid="B84">84</xref>,<xref ref-type="bibr" rid="B85">85</xref>]. The substrates of &#x003b3;-secretase include proteins involved in neurite outgrowth and synapse formation as well as cell fate decisions and adhesion [<xref ref-type="bibr" rid="B84">84</xref>]. Presenilin has also other functions independent of &#x003b3;-secretase, including roles in organelle transport and turnover, Akt-ERK signaling, cytoskeletal dynamics, and as a calcium leak channel in the endoplasmic reticulum [<xref ref-type="bibr" rid="B86">86</xref>].</p><p>The IL-18 induction of A&#x003b2; was abolished by the simultaneous treatment with IL-18&#x02009;bp. Interestingly, IL-18 also increased A&#x003b2; production in normal human astrocytes similar to the effects of IFN-&#x003b3; and H<sub>2</sub>O<sub>2</sub>, whereas IL-1&#x003b2; had only a very minor impact. The normal function of astrocytic A&#x003b2; is not understood, although glia, which are more abundant than neurons, may substantially contribute to the A&#x003b2;-plaque formation when the amyloidogenic cleavage system is activated in astrocytes. The A&#x003b2;-plaques are primarily made of A&#x003b2; peptides 1 to 40 and 1 to 42, both forms elevated in AD, but particularly A&#x003b2;42 is correlated with AD cognitive decline [<xref ref-type="bibr" rid="B87">87</xref>-<xref ref-type="bibr" rid="B89">89</xref>]. However, A&#x003b2; is also produced as part of normal metabolism and can be detected in the blood [<xref ref-type="bibr" rid="B90">90</xref>] and cerebrospinal fluid [<xref ref-type="bibr" rid="B91">91</xref>]. Physiological level of A&#x003b2; may regulate synaptic function and keep neuronal hyperactivity in check by negative feedback [<xref ref-type="bibr" rid="B92">92</xref>]. When accumulated inside the cells, A&#x003b2; is toxic [<xref ref-type="bibr" rid="B93">93</xref>,<xref ref-type="bibr" rid="B94">94</xref>] and can disrupt synaptic function [<xref ref-type="bibr" rid="B92">92</xref>]. Thus IL-18 in both neurons and astrocytes may contribute to enhancing A&#x003b2; effects, both positive and negative, particularly in the aged neurons.</p><p>Alterations in APP processing were also apparent in the culture medium. The ratio of sAPP&#x003b2; to sAPP&#x003b1; increased following IL-18 treatment. sAPP&#x003b1;, reduced in familial and sporadic AD patients [<xref ref-type="bibr" rid="B95">95</xref>], has been implicated in neurite outgrowth [<xref ref-type="bibr" rid="B96">96</xref>], neuroprotection [<xref ref-type="bibr" rid="B97">97</xref>], neurotrophism and adult neurogenesis [<xref ref-type="bibr" rid="B98">98</xref>], axonal transport [<xref ref-type="bibr" rid="B99">99</xref>], synaptic function [<xref ref-type="bibr" rid="B92">92</xref>], and transcriptional regulation [<xref ref-type="bibr" rid="B100">100</xref>]. sAPP&#x003b2; in turn can robustly drive neural differentiation of human embryonic stem cells [<xref ref-type="bibr" rid="B101">101</xref>]. Thus, IL-18, via sAPP&#x003b2; to sAPP&#x003b1; ratio will modulate neural differentiation and survival functions.</p><p>The CTFs of APP, increased in AD patients&#x02019; brains, may be more neurotoxic than A&#x003b2;. These CTFs have been shown to impair calcium homeostasis as well as learning and memory through blocking LTP [<xref ref-type="bibr" rid="B102">102</xref>]. The cleavage of the C99 fragment through residues 48 to 50 by &#x003b3;-secretase generates AICD59 (Figure <xref ref-type="fig" rid="F1">1</xref>), which can interact with several binders, including the phosphotyrosine interaction domain of Fe65 [<xref ref-type="bibr" rid="B72">72</xref>] to form a transcriptionally active complex. We showed that IL-18 increases protein level of Fe65 (approximately 77 kD). However, the phosphorylation of Thr668 in AICD is essential for its binding to Fe65 and to nuclear translocation, where it forms a ternary complex with transcription factor CP2/LSF/LBP1. This complex functions as a transcriptional activator for GSK-3&#x003b2;, APP, and BACE, as well as for transgelin, &#x003b1;2-actin, IGFBP3, and A&#x003b2; degrading neprilysin [<xref ref-type="bibr" rid="B103">103</xref>]. In our previous study [<xref ref-type="bibr" rid="B19">19</xref>] we found increased levels of GSK-3&#x003b2; after IL-18 treatments. Whether Fe65 mediated this remains to be determined. GSK-3&#x003b2; also regulates the CTF of PS-1 through its Ser397 phosphorylation [<xref ref-type="bibr" rid="B57">57</xref>], likely to decrease &#x003b3;-secretase activity and altering the balance of C99 and A&#x003b2;.</p><p>The early phase of A&#x003b2;42-induced cytotoxicity in neuronal cells is associated with vacuole formation and enhancement of exocytosis [<xref ref-type="bibr" rid="B104">104</xref>]. A suggestion of increased vacuolization in IL-18 treated cells was apparent at the final time point. Since caspase-3 activation can be induced by A&#x003b2; leading to apoptosis [<xref ref-type="bibr" rid="B105">105</xref>], we also examined protein levels of caspase-3. Protein level of pro-caspase-3 (32 kD) altered time-dependently indicating its processing to the functional tetrameric complex. On the other hand, the tetrameric 58 kD form of caspase-3 increased only very modestly in IL-18 treated cells. Although caspase-3 is implicated in APP processing into amyloidogenic fragments with the accumulation of caspase-cleaved APP evident in the early phases of AD [<xref ref-type="bibr" rid="B52">52</xref>], the role of caspase-3 in APP processing when the amyloidogenic processing machinery is activated is unknown.</p><p>Bcl-xL is a negative regulator of caspase-3 activation in immature neurons during development [<xref ref-type="bibr" rid="B106">106</xref>]. Caspase-3 and bcl-xL also seem to have epistatic and independent functions in developmental programmed cell death [<xref ref-type="bibr" rid="B107">107</xref>]. Bcl-xL protects neurons from A&#x003b2; neurotoxicity, as shown in bcl-xL over-expressing SH-SY5Y cells [<xref ref-type="bibr" rid="B108">108</xref>]. In our studies, protein levels of bcl-xL were slightly increased at the final time-point by IL-18 treatment, suggesting a counteracting of caspase-3 apoptotic processes.</p><p>In conclusion, the present study shows that IL-18 increases APP expression and phosphorylation, which precede increased BACE-1 levels. The IL-18 induction of BACE-1, APP processing and A&#x003b2; is likely to be linked to stress associated adaptations in neurons and glia during the course of normal functioning and development. Further, in our cell culture system the limiting factor for A&#x003b2; production seemed to involve PS-1, the activation of which may require more enhanced expression of Pen-2 or other factors, influenced by other mediators than IL-18. However, in the course of wider changes in the aging brain, and particularly in AD brain, the effects of heightened or prolonged levels of IL-18 may contribute to the process of AD, including via increased A&#x003b2;.</p></sec><sec><title>Abbreviations</title><p>A&#x003b2;, Amyloid-&#x003b2;; AD, Alzheimer&#x02019;s disease; ADAM, A Disintegrin and Metalloproteinase domain-containing protein; AICD, Amyloid precursor protein Intracellular Cytoplasmic/C-terminal Domain; Aph, Anterior pharynx-defective; APLP, Amyloid precursor-like protein; APP, Amyloid precursor protein; ATRA, All trans retinoic acid; BACE-1, &#x003b2;-site amyloid precursor protein cleaving enzyme; bcl-xL, B-cell lymphoma-extra large; bp, Binding protein; Cdk5, Cyclin dependent kinase 5; CNS, Central nervous system; CTF, C-terminal fragment; ERK, Extracellular signal-regulated kinase; GSK-3, Glycogen synthase kinase-3; H<sub>2</sub>O<sub>2</sub>, Hydrogen peroxide; IGFBP, Insulin-like growth factor binding protein; IL, Interleukin; IL-18&#x02009;bp, IL-18 binding protein; IL-18R, IL-18 receptor; IFN-&#x003b3;, Interferon-&#x003b3;; JNK, c-Jun N-terminal kinase; LDH, Lactate dehydrogenase; LPS, Lipopolysaccharide; LTP, Long-term Potentiation; NTF, N-terminal fragment; NF-&#x003ba;B, Nuclear factor &#x003ba;-light-chain-enhancer of activated B cells; Pen-2, Presenilin enhancer 2; PS-1, Presenilin-1.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors&#x02019; contributions</title><p>ES and JO carried out the cell culture, laboratory work, and analyses; JO, TP, AS, and ES contributed to the design of the study; TP and ES provided the research support. JO, ES, and GA wrote the manuscript. All authors read and approved the final version of the manuscript.</p></sec></body><back><sec><title>Acknowledgements</title><p>This study is funded by the Academy of Finland (grant 110320, Professor T Pirttil&#x000e4;), Finnish Cultural Foundation; North Savo Regional Fund (EM Sutinen) and in part by the Nordic Centre of Excellence. Our warm thanks to technician Aila Sepp&#x000e4;nen for her skillful help.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Carpentier</surname><given-names>M</given-names></name><name><surname>Robitaille</surname><given-names>Y</given-names></name><name><surname>DesGroseillers</surname><given-names>L</given-names></name><name><surname>Boileau</surname><given-names>G</given-names></name><name><surname>Marcinkiewicz</surname><given-names>M</given-names></name><article-title>Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy</article-title><source>J Neuropathol Exp Neurol</source><year>2002</year><volume>61</volume><fpage>849</fpage><lpage>856</lpage><comment>OvidSP_UI03.05.01.104, SourceID 55663</comment><pub-id pub-id-type="pmid">12387451</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Mattson</surname><given-names>MP</given-names></name><name><surname>Rydel</surname><given-names>RE</given-names></name><article-title>Amyloid ox-tox transducers</article-title><source>Nature</source><year>1996</year><volume>382</volume><fpage>674</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1038/382674a0</pub-id><pub-id pub-id-type="pmid">8751434</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Olney</surname><given-names>JW</given-names></name><name><surname>Wozniak</surname><given-names>DF</given-names></name><name><surname>Farber</surname><given-names>NB</given-names></name><article-title>Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies</article-title><source>Arch Neurol</source><year>1997</year><volume>54</volume><fpage>1234</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.1001/archneur.1997.00550220042012</pub-id><pub-id pub-id-type="pmid">9341569</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Heneka</surname><given-names>MT</given-names></name><name><surname>O&#x02019;Banion</surname><given-names>MK</given-names></name><article-title>Inflammatory processes in Alzheimer&#x02019;s disease</article-title><source>J Neuroimmunol</source><year>2007</year><volume>184</volume><fpage>69</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2006.11.017</pub-id><pub-id pub-id-type="pmid">17222916</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Wyss-Coray</surname><given-names>T</given-names></name><article-title>Inflammation in Alzheimer disease: driving force, bystander or beneficial response?</article-title><source>Nat Med</source><year>2006</year><volume>12</volume><fpage>1005</fpage><lpage>1015</lpage><pub-id pub-id-type="pmid">16960575</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Wyss-Coray</surname><given-names>T</given-names></name><name><surname>Rogers</surname><given-names>J</given-names></name><article-title>Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature</article-title><source>Cold Spring Harb Perspect Med</source><year>2012</year><volume>2</volume><fpage>1</fpage><lpage>23</lpage></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Bauer</surname><given-names>J</given-names></name><name><surname>Strauss</surname><given-names>S</given-names></name><name><surname>Schreiter-Gasser</surname><given-names>U</given-names></name><name><surname>Ganter</surname><given-names>U</given-names></name><name><surname>Schlegel</surname><given-names>P</given-names></name><name><surname>Witt</surname><given-names>I</given-names></name><name><surname>Yolk</surname><given-names>B</given-names></name><name><surname>Berger</surname><given-names>M</given-names></name><article-title>Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer&#x02019;s disease cortices</article-title><source>FEBS Lett</source><year>1991</year><volume>285</volume><fpage>111</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/0014-5793(91)80737-N</pub-id><pub-id pub-id-type="pmid">1712317</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Vandenabeele</surname><given-names>P</given-names></name><name><surname>Fiers</surname><given-names>W</given-names></name><article-title>Is amyloidogenesis during Alzheimer&#x02019;s disease due to an IL-1-/IL-6-mediated &#x02018;acute phase response&#x02019; in the brain?</article-title><source>Immunol Today</source><year>1991</year><volume>12</volume><fpage>217</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/0167-5699(91)90032-O</pub-id><pub-id pub-id-type="pmid">1909530</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Cacabelos</surname><given-names>R</given-names></name><name><surname>Alvarez</surname><given-names>XA</given-names></name><name><surname>Fernandez-Novoa</surname><given-names>L</given-names></name><name><surname>Franco</surname><given-names>A</given-names></name><name><surname>Mangues</surname><given-names>R</given-names></name><name><surname>Pellicer</surname><given-names>A</given-names></name><name><surname>Nishimura</surname><given-names>T</given-names></name><article-title>Brain interleukin-1 beta in Alzheimer&#x02019;s disease and vascular dementia</article-title><source>Methods Find Exp Clin Pharmacol</source><year>1994</year><volume>16</volume><fpage>141</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">8007743</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Griffin</surname><given-names>WS</given-names></name><name><surname>Sheng</surname><given-names>JG</given-names></name><name><surname>Royston</surname><given-names>MC</given-names></name><name><surname>Gentleman</surname><given-names>SM</given-names></name><name><surname>McKenzie</surname><given-names>JE</given-names></name><name><surname>Graham</surname><given-names>DI</given-names></name><name><surname>Roberts</surname><given-names>GW</given-names></name><name><surname>Mrak</surname><given-names>RE</given-names></name><article-title>Glial-neuronal interactions in Alzheimer&#x02019;s disease: the potential role of a &#x02018;cytokine cycle&#x02019; in disease progression</article-title><source>Brain Pathol</source><year>1998</year><volume>8</volume><fpage>65</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">9458167</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>KA</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Sakaki</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>CW</given-names></name><name><surname>Suh</surname><given-names>YH</given-names></name><article-title>Inhibition of the NGF and IL-1beta-induced expression of Alzheimer&#x02019;s amyloid precursor protein by antisense oligonucleotides</article-title><source>J Mol Neurosci</source><year>1999</year><volume>12</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1385/JMN:12:1:69</pub-id><pub-id pub-id-type="pmid">10636471</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Ojala</surname><given-names>J</given-names></name><name><surname>Alafuzoff</surname><given-names>I</given-names></name><name><surname>Herukka</surname><given-names>SK</given-names></name><name><surname>van Groen</surname><given-names>T</given-names></name><name><surname>Tanila</surname><given-names>H</given-names></name><name><surname>Pirttil&#x000e4;</surname><given-names>T</given-names></name><article-title>Expression of interleukin-18 is increased in the brains of Alzheimer&#x02019;s disease patients</article-title><source>Neurobiol Aging</source><year>2009</year><volume>30</volume><fpage>198</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2007.06.006</pub-id><pub-id pub-id-type="pmid">17658666</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Okamura</surname><given-names>H</given-names></name><name><surname>Tsutsui</surname><given-names>H</given-names></name><name><surname>Komatsu</surname><given-names>T</given-names></name><name><surname>Yutsudo</surname><given-names>M</given-names></name><name><surname>Hakura</surname><given-names>A</given-names></name><name><surname>Tanimoto</surname><given-names>T</given-names></name><name><surname>Torigoe</surname><given-names>K</given-names></name><name><surname>Okura</surname><given-names>T</given-names></name><name><surname>Nukada</surname><given-names>Y</given-names></name><name><surname>Hattori</surname><given-names>K</given-names></name><name><surname>Akita</surname><given-names>K</given-names></name><name><surname>Namba</surname><given-names>M</given-names></name><name><surname>Tanabe</surname><given-names>F</given-names></name><name><surname>Konishi</surname><given-names>K</given-names></name><name><surname>Fukuda</surname><given-names>S</given-names></name><name><surname>Kurimoto</surname><given-names>M</given-names></name><article-title>Cloning of a new cytokine that induces IFN-gamma production by T cells</article-title><source>Nature</source><year>1995</year><volume>378</volume><fpage>88</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1038/378088a0</pub-id><pub-id pub-id-type="pmid">7477296</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Joosten</surname><given-names>LA</given-names></name><name><surname>Radstake</surname><given-names>TR</given-names></name><name><surname>Lubberts</surname><given-names>E</given-names></name><name><surname>van den Bersselaar</surname><given-names>LA</given-names></name><name><surname>van Riel</surname><given-names>PL</given-names></name><name><surname>van Lent</surname><given-names>PL</given-names></name><name><surname>Barrera</surname><given-names>P</given-names></name><name><surname>van den Berg</surname><given-names>WB</given-names></name><article-title>Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis</article-title><source>Arthritis Rheum</source><year>2003</year><volume>48</volume><fpage>339</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1002/art.10814</pub-id><pub-id pub-id-type="pmid">12571842</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Fantuzzi</surname><given-names>G</given-names></name><name><surname>Reed</surname><given-names>DA</given-names></name><name><surname>Qi</surname><given-names>M</given-names></name><name><surname>Scully</surname><given-names>S</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>Senaldi</surname><given-names>G</given-names></name><article-title>Role of interferon regulatory factor-1 in the regulation of IL-18 production and activity</article-title><source>Eur J Immunol</source><year>2001</year><volume>31</volume><fpage>369</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1002/1521-4141(200102)31:2&#x0003c;369::AID-IMMU369&#x0003e;3.0.CO;2-Y</pub-id><pub-id pub-id-type="pmid">11180100</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>Y-M</given-names></name><name><surname>Im</surname><given-names>JY</given-names></name><name><surname>Han</surname><given-names>SH</given-names></name><name><surname>Kang</surname><given-names>HS</given-names></name><name><surname>Choi</surname><given-names>I</given-names></name><article-title>IFN-&#x003b3; up-regulates IL-18 gene expression via IFN consensus sequence-binding protein and activator protein-1 elements in macrophages</article-title><source>J Immunol</source><year>2000</year><volume>165</volume><fpage>3198</fpage><lpage>3205</lpage><pub-id pub-id-type="pmid">10975835</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Conti</surname><given-names>B</given-names></name><name><surname>Park</surname><given-names>LC</given-names></name><name><surname>Calingasan</surname><given-names>NY</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Bae</surname><given-names>Y</given-names></name><name><surname>Gibson</surname><given-names>GE</given-names></name><name><surname>Joh</surname><given-names>TH</given-names></name><article-title>Cultures of astrocytes and microglia express interleukin 18</article-title><source>Brain Res Mol Brain Res</source><year>1999</year><volume>67</volume><fpage>46</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">10101231</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Sugama</surname><given-names>S</given-names></name><name><surname>Cho</surname><given-names>BP</given-names></name><name><surname>Baker</surname><given-names>H</given-names></name><name><surname>Joh</surname><given-names>TH</given-names></name><name><surname>Lucero</surname><given-names>J</given-names></name><name><surname>Conti</surname><given-names>B</given-names></name><article-title>Neurons of the superior nucleus of the medial habenula and ependymal cells express IL-18 in rat CNS</article-title><source>Brain Res</source><year>2002</year><volume>958</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(02)03363-2</pub-id><pub-id pub-id-type="pmid">12468024</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Ojala</surname><given-names>JO</given-names></name><name><surname>Sutinen</surname><given-names>EM</given-names></name><name><surname>Salminen</surname><given-names>A</given-names></name><name><surname>Pirttil&#x000e4;</surname><given-names>T</given-names></name><article-title>Interleukin-18 increases expression of kinases involved in tau phosphorylation in SH-SY5Y neuroblastoma cells</article-title><source>J Neuroimmunol</source><year>2008</year><volume>205</volume><fpage>86</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2008.09.012</pub-id><pub-id pub-id-type="pmid">18947885</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Blacker</surname><given-names>D</given-names></name><name><surname>Bertram</surname><given-names>L</given-names></name><name><surname>Saunders</surname><given-names>AJ</given-names></name><name><surname>Moscarillo</surname><given-names>TJ</given-names></name><name><surname>Albert</surname><given-names>MS</given-names></name><name><surname>Wiener</surname><given-names>H</given-names></name><name><surname>Perry</surname><given-names>RT</given-names></name><name><surname>Collins</surname><given-names>JS</given-names></name><name><surname>Harrell</surname><given-names>LE</given-names></name><name><surname>Go</surname><given-names>RC</given-names></name><name><surname>Mahoney</surname><given-names>A</given-names></name><name><surname>Beaty</surname><given-names>T</given-names></name><name><surname>Fallin</surname><given-names>MD</given-names></name><name><surname>Avramopoulos</surname><given-names>D</given-names></name><name><surname>Chase</surname><given-names>GA</given-names></name><name><surname>Folstein</surname><given-names>MF</given-names></name><name><surname>McInnis</surname><given-names>MG</given-names></name><name><surname>Bassett</surname><given-names>SS</given-names></name><name><surname>Doheny</surname><given-names>KJ</given-names></name><name><surname>Pugh</surname><given-names>EW</given-names></name><name><surname>Tanzi</surname><given-names>RE</given-names></name><collab>NIMH Genetics Initiative Alzheimer&#x02019;s Disease Study Group</collab><article-title>Results of a high-resolution genome screen of 437 Alzheimer&#x02019;s disease families</article-title><source>Hum Mol Genet</source><year>2003</year><volume>12</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddg007</pub-id><pub-id pub-id-type="pmid">12490529</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Nolan</surname><given-names>KF</given-names></name><name><surname>Greaves</surname><given-names>DR</given-names></name><name><surname>Waldmann</surname><given-names>H</given-names></name><article-title>The human interleukin 18 gene IL18 maps to 11q22.2-q22.3, closely linked to the DRD2 gene locus and distinct from mapped IDDM loci</article-title><source>Genomics</source><year>1998</year><volume>51</volume><fpage>161</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1006/geno.1998.5336</pub-id><pub-id pub-id-type="pmid">9693051</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Boss&#x000f9;</surname><given-names>P</given-names></name><name><surname>Ciaramella</surname><given-names>A</given-names></name><name><surname>Moro</surname><given-names>ML</given-names></name><name><surname>Bellincampi</surname><given-names>L</given-names></name><name><surname>Bernardini</surname><given-names>S</given-names></name><name><surname>Federici</surname><given-names>G</given-names></name><name><surname>Trequattrini</surname><given-names>A</given-names></name><name><surname>Macciardi</surname><given-names>F</given-names></name><name><surname>Spoletini</surname><given-names>I</given-names></name><name><surname>Di Iulio</surname><given-names>F</given-names></name><name><surname>Caltagirone</surname><given-names>C</given-names></name><name><surname>Spalletta</surname><given-names>G</given-names></name><article-title>Interleukin 18 gene polymorphisms predict risk and outcome of Alzheimer&#x02019;s disease</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2007</year><volume>78</volume><fpage>807</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2006.103242</pub-id><pub-id pub-id-type="pmid">17299019</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>JT</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>JH</given-names></name><name><surname>Sun</surname><given-names>YP</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Miao</surname><given-names>D</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><article-title>Interleukin-18 promoter polymorphisms and risk of late onset Alzheimer&#x02019;s disease</article-title><source>Brain Res</source><year>2009</year><volume>1253</volume><fpage>169</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">19073159</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Kalina</surname><given-names>U</given-names></name><name><surname>Ballas</surname><given-names>K</given-names></name><name><surname>Koyama</surname><given-names>N</given-names></name><name><surname>Kauschat</surname><given-names>D</given-names></name><name><surname>Miething</surname><given-names>C</given-names></name><name><surname>Arnemann</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>H</given-names></name><name><surname>Hoelzer</surname><given-names>D</given-names></name><name><surname>Ottmann</surname><given-names>OG</given-names></name><article-title>Genomic organization and regulation of the human interleukin-18 gene</article-title><source>Scand J Immunol</source><year>2000</year><volume>52</volume><fpage>525</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1046/j.1365-3083.2000.00836.x</pub-id><pub-id pub-id-type="pmid">11119255</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Giedraitis</surname><given-names>V</given-names></name><name><surname>He</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>WX</given-names></name><name><surname>Hillert</surname><given-names>J</given-names></name><article-title>Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation</article-title><source>J Neuroimmunol</source><year>2001</year><volume>112</volume><fpage>146</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/S0165-5728(00)00407-0</pub-id><pub-id pub-id-type="pmid">11108943</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Segat</surname><given-names>L</given-names></name><name><surname>Milanese</surname><given-names>M</given-names></name><name><surname>Arosio</surname><given-names>B</given-names></name><name><surname>Vergani</surname><given-names>C</given-names></name><name><surname>Crovella</surname><given-names>S</given-names></name><article-title>Lack of association between Interleukin-18 gene promoter polymorphisms and onset of Alzheimer&#x02019;s disease</article-title><source>Neurobiol Aging</source><year>2010</year><volume>31</volume><fpage>162</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2008.03.005</pub-id><pub-id pub-id-type="pmid">18433937</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Boss&#x000f9;</surname><given-names>P</given-names></name><name><surname>Ciaramella</surname><given-names>A</given-names></name><name><surname>Salani</surname><given-names>F</given-names></name><name><surname>Bizzoni</surname><given-names>F</given-names></name><name><surname>Varsi</surname><given-names>E</given-names></name><name><surname>Di Iulio</surname><given-names>F</given-names></name><name><surname>Giubilei</surname><given-names>F</given-names></name><name><surname>Gianni</surname><given-names>W</given-names></name><name><surname>Trequattrini</surname><given-names>A</given-names></name><name><surname>Moro</surname><given-names>ML</given-names></name><name><surname>Bernardini</surname><given-names>S</given-names></name><name><surname>Caltagirone</surname><given-names>C</given-names></name><name><surname>Spalletta</surname><given-names>G</given-names></name><article-title>Interleukin-18 produced by peripheral blood cells is increased in Alzheimer&#x02019;s disease and correlates with cognitive impairment</article-title><source>Brain Behav Immun</source><year>2008</year><volume>22</volume><fpage>487</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2007.10.001</pub-id><pub-id pub-id-type="pmid">17988833</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Malaguarnera</surname><given-names>L</given-names></name><name><surname>Motta</surname><given-names>M</given-names></name><name><surname>Di Rosa</surname><given-names>M</given-names></name><name><surname>Anzaldi</surname><given-names>M</given-names></name><name><surname>Malaguarnera</surname><given-names>M</given-names></name><article-title>Interleukin-18 and transforming growth factor-beta 1 plasma levels in Alzheimer&#x02019;s disease and vascular dementia</article-title><source>Neuropathology</source><year>2006</year><volume>26</volume><fpage>307</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1789.2006.00701.x</pub-id><pub-id pub-id-type="pmid">16961066</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Ciaramella</surname><given-names>A</given-names></name><name><surname>Sanarico</surname><given-names>N</given-names></name><name><surname>Bizzoni</surname><given-names>F</given-names></name><name><surname>Moro</surname><given-names>ML</given-names></name><name><surname>Salani</surname><given-names>F</given-names></name><name><surname>Scapigliati</surname><given-names>G</given-names></name><name><surname>Spalletta</surname><given-names>G</given-names></name><name><surname>Caltagirone</surname><given-names>C</given-names></name><name><surname>Boss&#x000f9;</surname><given-names>P</given-names></name><article-title>Amyloid beta peptide promotes differentiation of pro-inflammatory human myeloid dendritic cells</article-title><source>Neurobiol Aging</source><year>2009</year><volume>30</volume><fpage>210</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2007.06.007</pub-id><pub-id pub-id-type="pmid">17658667</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Suk</surname><given-names>K</given-names></name><name><surname>Yeou Kim</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><article-title>Regulation of IL-18 production by IFN gamma and PGE2 in mouse microglial cells: involvement of NF-kB pathway in the regulatory processes</article-title><source>Immunol Lett</source><year>2001</year><volume>77</volume><fpage>79</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/S0165-2478(01)00209-7</pub-id><pub-id pub-id-type="pmid">11377701</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Chandrasekar</surname><given-names>B</given-names></name><name><surname>Valente</surname><given-names>AJ</given-names></name><name><surname>Freeman</surname><given-names>GL</given-names></name><name><surname>Mahimainathan</surname><given-names>L</given-names></name><name><surname>Mummidi</surname><given-names>S</given-names></name><article-title>Interleukin-18 induces human cardiac endothelial cell death via a novel signaling pathway involving NF-kappaB-dependent PTEN activation</article-title><source>Biochem Biophys Res Commun</source><year>2006</year><volume>339</volume><fpage>956</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2005.11.100</pub-id><pub-id pub-id-type="pmid">16325763</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Kanno</surname><given-names>T</given-names></name><name><surname>Nagata</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Okamura</surname><given-names>H</given-names></name><name><surname>Nishizaki</surname><given-names>T</given-names></name><article-title>Interleukin-18 stimulates synaptically released glutamate and enhances postsynaptic AMPA receptor responses in the CA1 region of mouse hippocampal slices</article-title><source>Brain Res</source><year>2004</year><volume>1012</volume><fpage>190</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2004.03.065</pub-id><pub-id pub-id-type="pmid">15158178</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Pickering</surname><given-names>M</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>JJ</given-names></name><article-title>Pro-inflammatory cytokines and their effects in the dentate gyrus</article-title><source>Prog Brain Res</source><year>2007</year><volume>163</volume><fpage>339</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">17765728</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Mallat</surname><given-names>Z</given-names></name><name><surname>Corbaz</surname><given-names>A</given-names></name><name><surname>Scoazec</surname><given-names>A</given-names></name><name><surname>Besnard</surname><given-names>S</given-names></name><name><surname>Les&#x000e8;che</surname><given-names>G</given-names></name><name><surname>Chvatchko</surname><given-names>Y</given-names></name><name><surname>Tedgui</surname><given-names>A</given-names></name><article-title>Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability</article-title><source>Circulation</source><year>2001</year><volume>104</volume><fpage>1598</fpage><lpage>1603</lpage><pub-id pub-id-type="doi">10.1161/hc3901.096721</pub-id><pub-id pub-id-type="pmid">11581135</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Aso</surname><given-names>Y</given-names></name><name><surname>Okumura</surname><given-names>K</given-names></name><name><surname>Takebayashi</surname><given-names>K</given-names></name><name><surname>Wakabayashi</surname><given-names>S</given-names></name><name><surname>Inukai</surname><given-names>T</given-names></name><article-title>Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes</article-title><source>Diabetes Care</source><year>2003</year><volume>26</volume><fpage>2622</fpage><lpage>2627</lpage><pub-id pub-id-type="doi">10.2337/diacare.26.9.2622</pub-id><pub-id pub-id-type="pmid">12941729</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Hayden</surname><given-names>KM</given-names></name><name><surname>Zandi</surname><given-names>PP</given-names></name><name><surname>Lyketsos</surname><given-names>CG</given-names></name><name><surname>Khachaturian</surname><given-names>AS</given-names></name><name><surname>Bastian</surname><given-names>LA</given-names></name><name><surname>Charoonruk</surname><given-names>G</given-names></name><name><surname>Tschanz</surname><given-names>JT</given-names></name><name><surname>Norton</surname><given-names>MC</given-names></name><name><surname>Pieper</surname><given-names>CF</given-names></name><name><surname>Munger</surname><given-names>RG</given-names></name><name><surname>Breitner</surname><given-names>JC</given-names></name><name><surname>Welsh-Bohmer</surname><given-names>KA</given-names></name><article-title>Cache County Investigators: Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study</article-title><source>Alzheimer Dis Assoc Disord</source><year>2006</year><volume>20</volume><fpage>93</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1097/01.wad.0000213814.43047.86</pub-id><pub-id pub-id-type="pmid">16772744</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Qiu</surname><given-names>C</given-names></name><name><surname>De Ronchi</surname><given-names>D</given-names></name><name><surname>Fratiglioni</surname><given-names>L</given-names></name><article-title>The epidemiology of the dementias: an update</article-title><source>Curr Opin Psychiatry</source><year>2007</year><volume>20</volume><fpage>380</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1097/YCO.0b013e32816ebc7b</pub-id><pub-id pub-id-type="pmid">17551353</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Sugama</surname><given-names>S</given-names></name><name><surname>Conti</surname><given-names>B</given-names></name><article-title>Interleukin-18 and stress</article-title><source>Brain Res Rev</source><year>2008</year><volume>58</volume><fpage>85</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.brainresrev.2007.11.003</pub-id><pub-id pub-id-type="pmid">18295340</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Yaguchi</surname><given-names>T</given-names></name><name><surname>Nagata</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Nishizaki</surname><given-names>T</given-names></name><article-title>Interleukin-18 regulates motor activity, anxiety and spatial learning without affecting synaptic plasticity</article-title><source>Behav Brain Res</source><year>2010</year><volume>206</volume><fpage>47</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2009.08.033</pub-id><pub-id pub-id-type="pmid">19729040</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Kristo</surname><given-names>C</given-names></name><name><surname>Godang</surname><given-names>K</given-names></name><name><surname>Ueland</surname><given-names>T</given-names></name><name><surname>Lien</surname><given-names>E</given-names></name><name><surname>Aukrust</surname><given-names>P</given-names></name><name><surname>Froland</surname><given-names>SS</given-names></name><name><surname>Bollerslev</surname><given-names>J</given-names></name><article-title>Raised serum levels of interleukin-8 and interleukin-18 in relation to bone metabolism in endogenous Cushing&#x02019;s syndrome</article-title><source>Eur J Endocrinol</source><year>2002</year><volume>146</volume><fpage>389</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1530/eje.0.1460389</pub-id><pub-id pub-id-type="pmid">11888846</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Gardella</surname><given-names>S</given-names></name><name><surname>Andrei</surname><given-names>C</given-names></name><name><surname>Poggi</surname><given-names>A</given-names></name><name><surname>Zocchi</surname><given-names>MR</given-names></name><name><surname>Rubartelli</surname><given-names>A</given-names></name><article-title>Control of interleukin-18 secretion by dendritic cells: role of calcium influxes</article-title><source>FEBS Lett</source><year>2000</year><volume>481</volume><fpage>245</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(00)02015-9</pub-id><pub-id pub-id-type="pmid">11007972</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Sisodia</surname><given-names>SS</given-names></name><name><surname>Koo</surname><given-names>EH</given-names></name><name><surname>Beyreuther</surname><given-names>K</given-names></name><name><surname>Unterbeck</surname><given-names>A</given-names></name><name><surname>Price</surname><given-names>DL</given-names></name><article-title>Evidence that beta-amyloid protein in Alzheimer&#x02019;s disease is not derived by normal processing</article-title><source>Science</source><year>1990</year><volume>248</volume><fpage>492</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1126/science.1691865</pub-id><pub-id pub-id-type="pmid">1691865</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Ando</surname><given-names>K</given-names></name><name><surname>Oishi</surname><given-names>M</given-names></name><name><surname>Takeda</surname><given-names>S</given-names></name><name><surname>Iijima</surname><given-names>K</given-names></name><name><surname>Isohara</surname><given-names>T</given-names></name><name><surname>Nairn</surname><given-names>AC</given-names></name><name><surname>Kirino</surname><given-names>Y</given-names></name><name><surname>Greengard</surname><given-names>P</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><article-title>Role of phosphorylation of Alzheimer&#x02019;s amyloid precursor protein during neuronal differentiation</article-title><source>J Neurosci</source><year>1999</year><volume>19</volume><fpage>4421</fpage><lpage>4427</lpage><pub-id pub-id-type="pmid">10341243</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Fisher</surname><given-names>S</given-names></name><name><surname>Gearhart</surname><given-names>JD</given-names></name><name><surname>Oster-Granite</surname><given-names>ML</given-names></name><article-title>Expression of the amyloid precursor protein gene in mouse oocytes and embryos</article-title><source>Proc Natl Acad Sci USA</source><year>1991</year><volume>88</volume><fpage>1779</fpage><lpage>1782</lpage><pub-id pub-id-type="doi">10.1073/pnas.88.5.1779</pub-id><pub-id pub-id-type="pmid">1900367</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>L&#x000f3;pez-S&#x000e1;nchez</surname><given-names>N</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>U</given-names></name><name><surname>Frade</surname><given-names>JM</given-names></name><article-title>Lengthening of G2/mitosis in cortical precursors from mice lacking beta-amyloid precursor protein</article-title><source>Neuroscience</source><year>2005</year><volume>130</volume><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2004.09.020</pub-id><pub-id pub-id-type="pmid">15561424</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Pinnix</surname><given-names>I</given-names></name><name><surname>Musunuru</surname><given-names>U</given-names></name><name><surname>Tun</surname><given-names>H</given-names></name><name><surname>Sridharan</surname><given-names>A</given-names></name><name><surname>Golde</surname><given-names>T</given-names></name><name><surname>Eckman</surname><given-names>C</given-names></name><name><surname>Ziani-Cherif</surname><given-names>C</given-names></name><name><surname>Onstead</surname><given-names>L</given-names></name><name><surname>Sambamurti</surname><given-names>K</given-names></name><article-title>A novel gamma -secretase assay based on detection of the putative C-terminal fragment-gamma of amyloid beta protein precursor</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>481</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">11035007</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Vassar</surname><given-names>R</given-names></name><name><surname>Bennett</surname><given-names>BD</given-names></name><name><surname>Babu-Khan</surname><given-names>S</given-names></name><name><surname>Kahn</surname><given-names>S</given-names></name><name><surname>Mendiaz</surname><given-names>EA</given-names></name><name><surname>Denis</surname><given-names>P</given-names></name><name><surname>Teplow</surname><given-names>DB</given-names></name><name><surname>Ross</surname><given-names>S</given-names></name><name><surname>Amarante</surname><given-names>P</given-names></name><name><surname>Loeloff</surname><given-names>R</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Fisher</surname><given-names>S</given-names></name><name><surname>Fuller</surname><given-names>J</given-names></name><name><surname>Edenson</surname><given-names>S</given-names></name><name><surname>Lile</surname><given-names>J</given-names></name><name><surname>Jarosinski</surname><given-names>MA</given-names></name><name><surname>Biere</surname><given-names>AL</given-names></name><name><surname>Curran</surname><given-names>E</given-names></name><name><surname>Burgess</surname><given-names>T</given-names></name><name><surname>Louis</surname><given-names>JC</given-names></name><name><surname>Collins</surname><given-names>F</given-names></name><name><surname>Treanor</surname><given-names>J</given-names></name><name><surname>Rogers</surname><given-names>G</given-names></name><name><surname>Citron</surname><given-names>M</given-names></name><article-title>Beta-secretase cleavage of Alzheimer&#x02019;s amyloid precursor protein by the transmembrane aspartic protease BACE</article-title><source>Science</source><year>1999</year><volume>286</volume><fpage>735</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1126/science.286.5440.735</pub-id><pub-id pub-id-type="pmid">10531052</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Huse</surname><given-names>JT</given-names></name><name><surname>Pijak</surname><given-names>DS</given-names></name><name><surname>Leslie</surname><given-names>GJ</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Doms</surname><given-names>RW</given-names></name><article-title>Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer&#x02019;s disease beta-secretase</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>33729</fpage><lpage>33737</lpage><pub-id pub-id-type="doi">10.1074/jbc.M004175200</pub-id><pub-id pub-id-type="pmid">10924510</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Baulac</surname><given-names>S</given-names></name><name><surname>LaVoie</surname><given-names>MJ</given-names></name><name><surname>Kimberly</surname><given-names>WT</given-names></name><name><surname>Strahle</surname><given-names>J</given-names></name><name><surname>Wolfe</surname><given-names>MS</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><article-title>Functional gamma-secretase complex assembly in Golgi/trans-Golgi network: interactions among presenilin, nicastrin, Aph1, Pen-2, and gamma-secretase substrates</article-title><source>Neurobiol Dis</source><year>2003</year><volume>14</volume><fpage>194</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/S0969-9961(03)00123-2</pub-id><pub-id pub-id-type="pmid">14572442</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name><surname>Allinson</surname><given-names>TM</given-names></name><name><surname>Parkin</surname><given-names>ET</given-names></name><name><surname>Turner</surname><given-names>AJ</given-names></name><name><surname>Hooper</surname><given-names>NM</given-names></name><article-title>ADAMs family members as amyloid precursor protein alpha-secretases</article-title><source>J Neurosci Res</source><year>2003</year><volume>74</volume><fpage>342</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1002/jnr.10737</pub-id><pub-id pub-id-type="pmid">14598310</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><name><surname>Nikolaev</surname><given-names>A</given-names></name><name><surname>McLaughlin</surname><given-names>T</given-names></name><name><surname>O&#x02019;Leary</surname><given-names>DD</given-names></name><name><surname>Tessier-Lavigne</surname><given-names>M</given-names></name><article-title>APP binds DR6 to trigger axon pruning and neuron death via distinct caspases</article-title><source>Nature</source><year>2009</year><volume>457</volume><fpage>981</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1038/nature07767</pub-id><pub-id pub-id-type="pmid">19225519</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><name><surname>Gervais</surname><given-names>FG</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Robertson</surname><given-names>GS</given-names></name><name><surname>Vaillancourt</surname><given-names>JP</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>LeBlanc</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Rigby</surname><given-names>M</given-names></name><name><surname>Shearman</surname><given-names>MS</given-names></name><name><surname>Clarke</surname><given-names>EE</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Van Der Ploeg</surname><given-names>LH</given-names></name><name><surname>Ruffolo</surname><given-names>SC</given-names></name><name><surname>Thornberry</surname><given-names>NA</given-names></name><name><surname>Xanthoudakis</surname><given-names>S</given-names></name><name><surname>Zamboni</surname><given-names>RJ</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Nicholson</surname><given-names>DW</given-names></name><article-title>Involvement of caspases in proteolytic cleavage of Alzheimer&#x02019;s amyloid-beta precursor protein and amyloidogenic A beta peptide formation</article-title><source>Cell</source><year>1999</year><volume>97</volume><fpage>395</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80748-5</pub-id><pub-id pub-id-type="pmid">10319819</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><name><surname>Pastorino</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>PJ</given-names></name><name><surname>Zhou</surname><given-names>XZ</given-names></name><name><surname>Balastik</surname><given-names>M</given-names></name><name><surname>Finn</surname><given-names>G</given-names></name><name><surname>Wulf</surname><given-names>G</given-names></name><name><surname>Lim</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>SH</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Nicholson</surname><given-names>LK</given-names></name><name><surname>Lu</surname><given-names>KP</given-names></name><article-title>The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production</article-title><source>Nature</source><year>2006</year><volume>440</volume><fpage>528</fpage><lpage>534</lpage><comment>Erratum in: Nature 2007, 446:342</comment><pub-id pub-id-type="doi">10.1038/nature04543</pub-id><pub-id pub-id-type="pmid">16554819</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>MS</given-names></name><name><surname>Kao</surname><given-names>SC</given-names></name><name><surname>Lemere</surname><given-names>CA</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Tseng</surname><given-names>HC</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Neve</surname><given-names>R</given-names></name><name><surname>Ahlijanian</surname><given-names>MK</given-names></name><name><surname>Tsai</surname><given-names>LH</given-names></name><article-title>APP processing is regulated by cytoplasmic phosphorylation</article-title><source>J Cell Biol</source><year>2003</year><volume>163</volume><fpage>83</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1083/jcb.200301115</pub-id><pub-id pub-id-type="pmid">14557249</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Ryder</surname><given-names>J</given-names></name><name><surname>Gonzalez-DeWhitt</surname><given-names>P</given-names></name><name><surname>May</surname><given-names>PC</given-names></name><name><surname>Ni</surname><given-names>B</given-names></name><article-title>Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35/Cdk5 and p25/Cdk5</article-title><source>FEBS Lett</source><year>2003</year><volume>547</volume><fpage>193</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(03)00714-2</pub-id><pub-id pub-id-type="pmid">12860412</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Kim</surname><given-names>EM</given-names></name><name><surname>Lee</surname><given-names>JP</given-names></name><name><surname>Park</surname><given-names>CH</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Seo</surname><given-names>JH</given-names></name><name><surname>Chang</surname><given-names>KA</given-names></name><name><surname>Yu</surname><given-names>E</given-names></name><name><surname>Jeong</surname><given-names>SJ</given-names></name><name><surname>Chong</surname><given-names>YH</given-names></name><name><surname>Suh</surname><given-names>YH</given-names></name><article-title>C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3beta expression</article-title><source>FASEB J</source><year>2003</year><volume>17</volume><fpage>1951</fpage><lpage>1953</lpage><pub-id pub-id-type="pmid">12923068</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><name><surname>Kirschenbaum</surname><given-names>F</given-names></name><name><surname>Hsu</surname><given-names>SC</given-names></name><name><surname>Cordell</surname><given-names>B</given-names></name><name><surname>McCarthy</surname><given-names>JV</given-names></name><article-title>Glycogen synthase kinase-3beta regulates presenilin 1 C-terminal fragment levels</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>30701</fpage><lpage>30707</lpage><pub-id pub-id-type="doi">10.1074/jbc.M102849200</pub-id><pub-id pub-id-type="pmid">11402035</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><name><surname>Maesako</surname><given-names>M</given-names></name><name><surname>Uemura</surname><given-names>K</given-names></name><name><surname>Kubota</surname><given-names>M</given-names></name><name><surname>Hiyoshi</surname><given-names>K</given-names></name><name><surname>Ando</surname><given-names>K</given-names></name><name><surname>Kuzuya</surname><given-names>A</given-names></name><name><surname>Kihara</surname><given-names>T</given-names></name><name><surname>Asada</surname><given-names>M</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Kinoshita</surname><given-names>A</given-names></name><article-title>Effect of glycogen synthase kinase 3 &#x003b2;-mediated presenilin 1 phosphorylation on amyloid &#x003b2; production is negatively regulated by insulin receptor cleavage</article-title><source>Neuroscience</source><year>2011</year><volume>177</volume><fpage>298</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">21238544</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><name><surname>Sallmon</surname><given-names>H</given-names></name><name><surname>Hoene</surname><given-names>V</given-names></name><name><surname>Weber</surname><given-names>SC</given-names></name><name><surname>Dame</surname><given-names>C</given-names></name><article-title>Differentiation of human SH-SY5Y neuroblastoma cells by all-trans retinoic acid activates the interleukin-18 system</article-title><source>J Interferon Cytokine Res</source><year>2010</year><volume>30</volume><fpage>55</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1089/jir.2009.0036</pub-id><pub-id pub-id-type="pmid">20028206</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><name><surname>Bammens</surname><given-names>L</given-names></name><name><surname>Ch&#x000e1;vez-Guti&#x000e9;rrez</surname><given-names>L</given-names></name><name><surname>Tolia</surname><given-names>A</given-names></name><name><surname>Zwijsen</surname><given-names>A</given-names></name><name><surname>De Strooper</surname><given-names>B</given-names></name><article-title>Functional and topological analysis of Pen-2, the fourth subunit of the gamma-secretase complex</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>12271</fpage><lpage>12282</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.216978</pub-id><pub-id pub-id-type="pmid">21296884</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Sisodia</surname><given-names>SS</given-names></name><article-title>A sequence within the first transmembrane domain of PEN-2 is critical for PEN-2-mediated endoproteolysis of presenilin 1</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>1992</fpage><lpage>2001</lpage><pub-id pub-id-type="pmid">15537629</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><name><surname>Kuhn</surname><given-names>PH</given-names></name><name><surname>Marjaux</surname><given-names>E</given-names></name><name><surname>Imhof</surname><given-names>A</given-names></name><name><surname>De Strooper</surname><given-names>B</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name><name><surname>Lichtenthaler</surname><given-names>SF</given-names></name><article-title>Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase</article-title><source>J Biol Chem</source><year>2007</year><volume>282</volume><fpage>11982</fpage><lpage>11995</lpage><pub-id pub-id-type="pmid">17307738</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><name><surname>Thomassen</surname><given-names>E</given-names></name><name><surname>Bird</surname><given-names>TA</given-names></name><name><surname>Renshaw</surname><given-names>BR</given-names></name><name><surname>Kennedy</surname><given-names>MK</given-names></name><name><surname>Sims</surname><given-names>JE</given-names></name><article-title>Binding of interleukin-18 to the interleukin-1 receptor homologous receptor IL-1Rrp1 leads to activation of signaling pathways similar to those used by interleukin-1</article-title><source>J Interferon Cytokine Res</source><year>1998</year><volume>18</volume><fpage>1077</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1089/jir.1998.18.1077</pub-id><pub-id pub-id-type="pmid">9877452</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><name><surname>Alboni</surname><given-names>S</given-names></name><name><surname>Cervia</surname><given-names>D</given-names></name><name><surname>Sugama</surname><given-names>S</given-names></name><name><surname>Conti</surname><given-names>B</given-names></name><article-title>Interleukin 18 in the CNS</article-title><source>J Neuroinflammation</source><year>2010</year><volume>7</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1186/1742-2094-7-1</pub-id><pub-id pub-id-type="pmid">20047691</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Shiojiri</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Kitaguchi</surname><given-names>N</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name><name><surname>Kameyama</surname><given-names>M</given-names></name><name><surname>Kimura</surname><given-names>J</given-names></name><name><surname>Nakamura</surname><given-names>S</given-names></name><name><surname>Ueda</surname><given-names>K</given-names></name><article-title>Tissue-specific expression of three types of beta-protein precursor mRNA: enhancement of protease inhibitor-harboring types in Alzheimer&#x02019;s disease brain</article-title><source>Biochem Biophys Res Commun</source><year>1989</year><volume>165</volume><fpage>1406</fpage><lpage>1414</lpage><pub-id pub-id-type="doi">10.1016/0006-291X(89)92760-5</pub-id><pub-id pub-id-type="pmid">2514687</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><name><surname>Herms</surname><given-names>J</given-names></name><name><surname>Anliker</surname><given-names>B</given-names></name><name><surname>Heber</surname><given-names>S</given-names></name><name><surname>Ring</surname><given-names>S</given-names></name><name><surname>Fuhrmann</surname><given-names>M</given-names></name><name><surname>Kretzschmar</surname><given-names>H</given-names></name><name><surname>Sisodia</surname><given-names>S</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>U</given-names></name><article-title>Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members</article-title><source>EMBO J</source><year>2004</year><volume>23</volume><fpage>4106</fpage><lpage>4115</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600390</pub-id><pub-id pub-id-type="pmid">15385965</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><name><surname>Young-Pearse</surname><given-names>TL</given-names></name><name><surname>Bai</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>R</given-names></name><name><surname>Zheng</surname><given-names>JB</given-names></name><name><surname>LoTurco</surname><given-names>JJ</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>A critical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference</article-title><source>J Neurosci</source><year>2007</year><volume>27</volume><fpage>14459</fpage><lpage>14469</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4701-07.2007</pub-id><pub-id pub-id-type="pmid">18160654</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><name><surname>Allinquant</surname><given-names>B</given-names></name><name><surname>Hantraye</surname><given-names>P</given-names></name><name><surname>Mailleux</surname><given-names>P</given-names></name><name><surname>Moya</surname><given-names>K</given-names></name><name><surname>Bouillot</surname><given-names>C</given-names></name><name><surname>Prochiantz</surname><given-names>A</given-names></name><article-title>Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro</article-title><source>J Cell Biol</source><year>1995</year><volume>128</volume><fpage>919</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1083/jcb.128.5.919</pub-id><pub-id pub-id-type="pmid">7876315</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><name><surname>Ikin</surname><given-names>AF</given-names></name><name><surname>Sabo</surname><given-names>SL</given-names></name><name><surname>Lanier</surname><given-names>LM</given-names></name><name><surname>Buxbaum</surname><given-names>JD</given-names></name><article-title>A macromolecular complex involving the amyloid precursor protein (APP) and the cytosolic adapter FE65 is a negative regulator of axon branching</article-title><source>Mol Cell Neurosci</source><year>2007</year><volume>35</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.mcn.2007.02.003</pub-id><pub-id pub-id-type="pmid">17383198</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><name><surname>Moya</surname><given-names>KL</given-names></name><name><surname>Benowitz</surname><given-names>LI</given-names></name><name><surname>Schneider</surname><given-names>GE</given-names></name><name><surname>Allinquant</surname><given-names>B</given-names></name><article-title>The amyloid precursor protein is developmentally regulated and correlated with synaptogenesis</article-title><source>Dev Biol</source><year>1994</year><volume>161</volume><fpage>597</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1006/dbio.1994.1055</pub-id><pub-id pub-id-type="pmid">8314003</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><name><surname>Weyer</surname><given-names>SW</given-names></name><name><surname>Klevanski</surname><given-names>M</given-names></name><name><surname>Delekate</surname><given-names>A</given-names></name><name><surname>Voikar</surname><given-names>V</given-names></name><name><surname>Aydin</surname><given-names>D</given-names></name><name><surname>Hick</surname><given-names>M</given-names></name><name><surname>Filippov</surname><given-names>M</given-names></name><name><surname>Drost</surname><given-names>N</given-names></name><name><surname>Schaller</surname><given-names>KL</given-names></name><name><surname>Saar</surname><given-names>M</given-names></name><name><surname>Vogt</surname><given-names>MA</given-names></name><name><surname>Gass</surname><given-names>P</given-names></name><name><surname>Samanta</surname><given-names>A</given-names></name><name><surname>J&#x000e4;schke</surname><given-names>A</given-names></name><name><surname>Korte</surname><given-names>M</given-names></name><name><surname>Wolfer</surname><given-names>DP</given-names></name><name><surname>Caldwell</surname><given-names>JH</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>UC</given-names></name><article-title>APP and APLP2 are essential at PNS and CNS synapses for transmission, spatial learning and LTP</article-title><source>EMBO J</source><year>2011</year><volume>30</volume><fpage>2266</fpage><lpage>2280</lpage><pub-id pub-id-type="doi">10.1038/emboj.2011.119</pub-id><pub-id pub-id-type="pmid">21522131</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>KA</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Ha</surname><given-names>TY</given-names></name><name><surname>Ha</surname><given-names>JW</given-names></name><name><surname>Shin</surname><given-names>KY</given-names></name><name><surname>Jeong</surname><given-names>YH</given-names></name><name><surname>Lee</surname><given-names>JP</given-names></name><name><surname>Park</surname><given-names>CH</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Baik</surname><given-names>TK</given-names></name><name><surname>Suh</surname><given-names>YH</given-names></name><article-title>Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration</article-title><source>Mol Cell Biol</source><year>2006</year><volume>26</volume><fpage>4327</fpage><lpage>4338</lpage><pub-id pub-id-type="doi">10.1128/MCB.02393-05</pub-id><pub-id pub-id-type="pmid">16705182</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><name><surname>Aplin</surname><given-names>AE</given-names></name><name><surname>Gibb</surname><given-names>GM</given-names></name><name><surname>Jacobsen</surname><given-names>JS</given-names></name><name><surname>Gallo</surname><given-names>JM</given-names></name><name><surname>Anderton</surname><given-names>BH</given-names></name><article-title>In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta</article-title><source>J Neurochem</source><year>1996</year><volume>67</volume><fpage>699</fpage><lpage>707</lpage><pub-id pub-id-type="pmid">8764598</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><name><surname>Phiel</surname><given-names>CJ</given-names></name><name><surname>Wilson</surname><given-names>CA</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Klein</surname><given-names>PS</given-names></name><article-title>GSK-3alpha regulates production of Alzheimer&#x02019;s disease amyloid-beta peptides</article-title><source>Nature</source><year>2003</year><volume>423</volume><fpage>435</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1038/nature01640</pub-id><pub-id pub-id-type="pmid">12761548</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><name><surname>Muresan</surname><given-names>Z</given-names></name><name><surname>Muresan</surname><given-names>V</given-names></name><article-title>The amyloid-beta precursor protein is phosphorylated via distinct pathways during differentiation, mitosis, stress, and degeneration</article-title><source>Mol Biol Cell</source><year>2007</year><volume>18</volume><fpage>3835</fpage><lpage>3844</lpage><pub-id pub-id-type="doi">10.1091/mbc.E06-07-0625</pub-id><pub-id pub-id-type="pmid">17634293</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><name><surname>Laird</surname><given-names>FM</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name><name><surname>Savonenko</surname><given-names>AV</given-names></name><name><surname>Farah</surname><given-names>MH</given-names></name><name><surname>He</surname><given-names>K</given-names></name><name><surname>Melnikova</surname><given-names>T</given-names></name><name><surname>Wen</surname><given-names>H</given-names></name><name><surname>Chiang</surname><given-names>HC</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Koliatsos</surname><given-names>VE</given-names></name><name><surname>Borchelt</surname><given-names>DR</given-names></name><name><surname>Price</surname><given-names>DL</given-names></name><name><surname>Lee</surname><given-names>HK</given-names></name><name><surname>Wong</surname><given-names>PC</given-names></name><article-title>BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions</article-title><source>J Neurosci</source><year>2005</year><volume>25</volume><fpage>11693</fpage><lpage>11709</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2766-05.2005</pub-id><pub-id pub-id-type="pmid">16354928</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><name><surname>Dominguez</surname><given-names>D</given-names></name><name><surname>Tournoy</surname><given-names>J</given-names></name><name><surname>Hartmann</surname><given-names>D</given-names></name><name><surname>Huth</surname><given-names>T</given-names></name><name><surname>Cryns</surname><given-names>K</given-names></name><name><surname>Deforce</surname><given-names>S</given-names></name><name><surname>Serneels</surname><given-names>L</given-names></name><name><surname>Camacho</surname><given-names>IE</given-names></name><name><surname>Marjaux</surname><given-names>E</given-names></name><name><surname>Craessaerts</surname><given-names>K</given-names></name><name><surname>Roebroek</surname><given-names>AJ</given-names></name><name><surname>Schwake</surname><given-names>M</given-names></name><name><surname>D&#x02019;Hooge</surname><given-names>R</given-names></name><name><surname>Bach</surname><given-names>P</given-names></name><name><surname>Kalinke</surname><given-names>U</given-names></name><name><surname>Moechars</surname><given-names>D</given-names></name><name><surname>Alzheimer</surname><given-names>C</given-names></name><name><surname>Reiss</surname><given-names>K</given-names></name><name><surname>Saftig</surname><given-names>P</given-names></name><name><surname>De Strooper</surname><given-names>B</given-names></name><article-title>Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>30797</fpage><lpage>30806</lpage><pub-id pub-id-type="doi">10.1074/jbc.M505249200</pub-id><pub-id pub-id-type="pmid">15987683</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><name><surname>Willem</surname><given-names>M</given-names></name><name><surname>Garratt</surname><given-names>AN</given-names></name><name><surname>Novak</surname><given-names>B</given-names></name><name><surname>Citron</surname><given-names>M</given-names></name><name><surname>Kaufmann</surname><given-names>S</given-names></name><name><surname>Rittger</surname><given-names>A</given-names></name><name><surname>DeStrooper</surname><given-names>B</given-names></name><name><surname>Saftig</surname><given-names>P</given-names></name><name><surname>Birchmeier</surname><given-names>C</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name><article-title>Control of peripheral nerve myelination by the beta-secretase BACE1</article-title><source>Science</source><year>2006</year><volume>314</volume><fpage>664</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1126/science.1132341</pub-id><pub-id pub-id-type="pmid">16990514</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Srivastava</surname><given-names>SY</given-names></name><name><surname>Brickey</surname><given-names>WJ</given-names></name><name><surname>Iocca</surname><given-names>H</given-names></name><name><surname>Toews</surname><given-names>A</given-names></name><name><surname>Morrison</surname><given-names>JP</given-names></name><name><surname>Chen</surname><given-names>VS</given-names></name><name><surname>Gris</surname><given-names>D</given-names></name><name><surname>Matsushima</surname><given-names>GK</given-names></name><name><surname>Ting</surname><given-names>JP</given-names></name><article-title>The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18</article-title><source>J Neurosci</source><year>2010</year><volume>30</volume><fpage>15811</fpage><lpage>15820</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4088-10.2010</pub-id><pub-id pub-id-type="pmid">21106820</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><name><surname>Blasko</surname><given-names>I</given-names></name><name><surname>Beer</surname><given-names>R</given-names></name><name><surname>Bigl</surname><given-names>M</given-names></name><name><surname>Apelt</surname><given-names>J</given-names></name><name><surname>Franz</surname><given-names>G</given-names></name><name><surname>Rudzki</surname><given-names>D</given-names></name><name><surname>Ransmayr</surname><given-names>G</given-names></name><name><surname>Kampfl</surname><given-names>A</given-names></name><name><surname>Schliebs</surname><given-names>R</given-names></name><article-title>Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase (BACE-1)</article-title><source>J Neural Transm</source><year>2004</year><volume>111</volume><fpage>523</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1007/s00702-003-0095-6</pub-id><pub-id pub-id-type="pmid">15057522</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><name><surname>Steiner</surname><given-names>H</given-names></name><name><surname>Winkler</surname><given-names>E</given-names></name><name><surname>Edbauer</surname><given-names>D</given-names></name><name><surname>Prokop</surname><given-names>S</given-names></name><name><surname>Basset</surname><given-names>G</given-names></name><name><surname>Yamasaki</surname><given-names>A</given-names></name><name><surname>Kostka</surname><given-names>M</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name><article-title>PEN-2 is an integral component of the gamma-secretase complex required for coordinated expression of presenilin and nicastrin</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>39062</fpage><lpage>39065</lpage><pub-id pub-id-type="doi">10.1074/jbc.C200469200</pub-id><pub-id pub-id-type="pmid">12198112</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Chen</surname><given-names>DF</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><name><surname>Tonegawa</surname><given-names>S</given-names></name><article-title>Skeletal and CNS defects in Presenilin-1-deficient mice</article-title><source>Cell</source><year>1997</year><volume>89</volume><fpage>629</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80244-5</pub-id><pub-id pub-id-type="pmid">9160754</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><name><surname>Gadadhar</surname><given-names>A</given-names></name><name><surname>Marr</surname><given-names>R</given-names></name><name><surname>Lazarov</surname><given-names>O</given-names></name><article-title>Presenilin-1 regulates neural progenitor cell differentiation in the adult brain</article-title><source>J Neurosci</source><year>2011</year><volume>31</volume><fpage>2615</fpage><lpage>2623</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4767-10.2011</pub-id><pub-id pub-id-type="pmid">21325529</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><name><surname>Spasic</surname><given-names>D</given-names></name><name><surname>Annaert</surname><given-names>W</given-names></name><article-title>Building gamma-secretase: the bits and pieces</article-title><source>J Cell Sci</source><year>2008</year><volume>121</volume><fpage>413</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1242/jcs.015255</pub-id><pub-id pub-id-type="pmid">18256384</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><name><surname>Hemming</surname><given-names>ML</given-names></name><name><surname>Elias</surname><given-names>JE</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name><article-title>Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements</article-title><source>PLoS Biol</source><year>2008</year><volume>6</volume><fpage>2314</fpage><lpage>2328</lpage></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><name><surname>Coen</surname><given-names>K</given-names></name><name><surname>Annaert</surname><given-names>W</given-names></name><article-title>Presenilins: how much more than &#x003b3;-secretase?!</article-title><source>Biochem Soc Trans</source><year>2010</year><volume>38</volume><fpage>1474</fpage><lpage>1478</lpage><pub-id pub-id-type="doi">10.1042/BST0381474</pub-id><pub-id pub-id-type="pmid">21118110</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><name><surname>McLean</surname><given-names>CA</given-names></name><name><surname>Cherny</surname><given-names>RA</given-names></name><name><surname>Fraser</surname><given-names>FW</given-names></name><name><surname>Fuller</surname><given-names>SJ</given-names></name><name><surname>Smith</surname><given-names>MJ</given-names></name><name><surname>Beyreuther</surname><given-names>K</given-names></name><name><surname>Bush</surname><given-names>AI</given-names></name><name><surname>Masters</surname><given-names>CL</given-names></name><article-title>Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer&#x02019;s disease</article-title><source>Ann Neurol</source><year>1999</year><volume>46</volume><fpage>860</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1002/1531-8249(199912)46:6&#x0003c;860::AID-ANA8&#x0003e;3.0.CO;2-M</pub-id><pub-id pub-id-type="pmid">10589538</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><name><surname>N&#x000e4;slund</surname><given-names>J</given-names></name><name><surname>Haroutunian</surname><given-names>V</given-names></name><name><surname>Mohs</surname><given-names>R</given-names></name><name><surname>Davis</surname><given-names>KL</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Greengard</surname><given-names>P</given-names></name><name><surname>Buxbaum</surname><given-names>JD</given-names></name><article-title>Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline</article-title><source>JAMA</source><year>2000</year><volume>283</volume><fpage>1571</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1001/jama.283.12.1571</pub-id><pub-id pub-id-type="pmid">10735393</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><name><surname>Lesn&#x000e9;</surname><given-names>S</given-names></name><name><surname>Koh</surname><given-names>MT</given-names></name><name><surname>Kotilinek</surname><given-names>L</given-names></name><name><surname>Kayed</surname><given-names>R</given-names></name><name><surname>Glabe</surname><given-names>CG</given-names></name><name><surname>Yang</surname><given-names>A</given-names></name><name><surname>Gallagher</surname><given-names>M</given-names></name><name><surname>Ashe</surname><given-names>KH</given-names></name><article-title>A specific amyloid-beta protein assembly in the brain impairs memory</article-title><source>Nature</source><year>2006</year><volume>440</volume><fpage>352</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/nature04533</pub-id><pub-id pub-id-type="pmid">16541076</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><name><surname>Lopez</surname><given-names>OL</given-names></name><name><surname>Kuller</surname><given-names>LH</given-names></name><name><surname>Mehta</surname><given-names>PD</given-names></name><name><surname>Becker</surname><given-names>JT</given-names></name><name><surname>Gach</surname><given-names>HM</given-names></name><name><surname>Sweet</surname><given-names>RA</given-names></name><name><surname>Chang</surname><given-names>YF</given-names></name><name><surname>Tracy</surname><given-names>R</given-names></name><name><surname>DeKosky</surname><given-names>ST</given-names></name><article-title>Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study</article-title><source>Neurology</source><year>2008</year><volume>70</volume><fpage>1664</fpage><lpage>1671</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000306696.82017.66</pub-id><pub-id pub-id-type="pmid">18401021</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><name><surname>Mawuenyega</surname><given-names>KG</given-names></name><name><surname>Sigurdson</surname><given-names>W</given-names></name><name><surname>Ovod</surname><given-names>V</given-names></name><name><surname>Munsell</surname><given-names>L</given-names></name><name><surname>Kasten</surname><given-names>T</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Yarasheski</surname><given-names>KE</given-names></name><name><surname>Bateman</surname><given-names>RJ</given-names></name><name><surname>Mawuenyega</surname><given-names>KG</given-names></name><name><surname>Sigurdson</surname><given-names>W</given-names></name><name><surname>Ovod</surname><given-names>V</given-names></name><name><surname>Munsell</surname><given-names>L</given-names></name><name><surname>Kasten</surname><given-names>T</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Yarasheski</surname><given-names>KE</given-names></name><name><surname>Bateman</surname><given-names>RJ</given-names></name><article-title>Decreased clearance of CNS beta-amyloid in Alzheimer&#x02019;s disease</article-title><source>Science</source><year>2010</year><volume>330</volume><fpage>1774</fpage><pub-id pub-id-type="doi">10.1126/science.1197623</pub-id><pub-id pub-id-type="pmid">21148344</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><name><surname>Kamenetz</surname><given-names>F</given-names></name><name><surname>Tomita</surname><given-names>T</given-names></name><name><surname>Hsieh</surname><given-names>H</given-names></name><name><surname>Seabrook</surname><given-names>G</given-names></name><name><surname>Borchelt</surname><given-names>D</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Sisodia</surname><given-names>S</given-names></name><name><surname>Malinow</surname><given-names>R</given-names></name><article-title>APP processing and synaptic function</article-title><source>Neuron</source><year>2003</year><volume>37</volume><fpage>925</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(03)00124-7</pub-id><pub-id pub-id-type="pmid">12670422</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><name><surname>Kienlen-Campard</surname><given-names>P</given-names></name><name><surname>Miolet</surname><given-names>S</given-names></name><name><surname>Tasiaux</surname><given-names>B</given-names></name><name><surname>Octave</surname><given-names>JN</given-names></name><article-title>Intracellular amyloid-beta 1&#x02013;42, but not extracellular soluble amyloid-beta peptides, induces neuronal apoptosis</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>15666</fpage><lpage>15670</lpage><pub-id pub-id-type="doi">10.1074/jbc.M200887200</pub-id><pub-id pub-id-type="pmid">11861655</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><name><surname>Magran&#x000e9;</surname><given-names>J</given-names></name><name><surname>Rosen</surname><given-names>KM</given-names></name><name><surname>Smith</surname><given-names>RC</given-names></name><name><surname>Walsh</surname><given-names>K</given-names></name><name><surname>Gouras</surname><given-names>GK</given-names></name><name><surname>Querfurth</surname><given-names>HW</given-names></name><article-title>Intraneuronal beta-amyloid expression downregulates the Akt survival pathway and blunts the stress response</article-title><source>J Neurosci</source><year>2005</year><volume>25</volume><fpage>10960</fpage><lpage>10969</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1723-05.2005</pub-id><pub-id pub-id-type="pmid">16306409</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><name><surname>Lannfelt</surname><given-names>L</given-names></name><name><surname>Basun</surname><given-names>H</given-names></name><name><surname>Wahlund</surname><given-names>LO</given-names></name><name><surname>Rowe</surname><given-names>BA</given-names></name><name><surname>Wagner</surname><given-names>SL</given-names></name><article-title>Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer&#x02019;s disease</article-title><source>Nat Med</source><year>1995</year><volume>1</volume><fpage>829</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1038/nm0895-829</pub-id><pub-id pub-id-type="pmid">7585189</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><name><surname>Gakhar-Koppole</surname><given-names>N</given-names></name><name><surname>Hundeshagen</surname><given-names>P</given-names></name><name><surname>Mandl</surname><given-names>C</given-names></name><name><surname>Weyer</surname><given-names>SW</given-names></name><name><surname>Allinquant</surname><given-names>B</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>U</given-names></name><name><surname>Ciccolini</surname><given-names>F</given-names></name><article-title>Activity requires soluble amyloid precursor protein alpha to promote neurite outgrowth in neural stem cell-derived neurons via activation of the MAPK pathway</article-title><source>Eur J Neurosci</source><year>2008</year><volume>28</volume><fpage>871</fpage><lpage>882</lpage><pub-id pub-id-type="doi">10.1111/j.1460-9568.2008.06398.x</pub-id><pub-id pub-id-type="pmid">18717733</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><name><surname>Perez</surname><given-names>RG</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Van der Ploeg</surname><given-names>LH</given-names></name><name><surname>Koo</surname><given-names>EH</given-names></name><article-title>The beta-amyloid precursor protein of Alzheimer&#x02019;s disease enhances neuron viability and modulates neuronal polarity</article-title><source>J Neurosci</source><year>1997</year><volume>17</volume><fpage>9407</fpage><lpage>9414</lpage><pub-id pub-id-type="pmid">9390996</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><name><surname>Caill&#x000e9;</surname><given-names>I</given-names></name><name><surname>Allinquant</surname><given-names>B</given-names></name><name><surname>Dupont</surname><given-names>E</given-names></name><name><surname>Bouillot</surname><given-names>C</given-names></name><name><surname>Langer</surname><given-names>A</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>U</given-names></name><name><surname>Prochiantz</surname><given-names>A</given-names></name><article-title>Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone</article-title><source>Development</source><year>2004</year><volume>131</volume><fpage>2173</fpage><lpage>2181</lpage><pub-id pub-id-type="doi">10.1242/dev.01103</pub-id><pub-id pub-id-type="pmid">15073156</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><name><surname>Kamal</surname><given-names>A</given-names></name><name><surname>Almenar-Queralt</surname><given-names>A</given-names></name><name><surname>LeBlanc</surname><given-names>JF</given-names></name><name><surname>Roberts</surname><given-names>EA</given-names></name><name><surname>Goldstein</surname><given-names>LS</given-names></name><article-title>Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP</article-title><source>Nature</source><year>2001</year><volume>414</volume><fpage>643</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1038/414643a</pub-id><pub-id pub-id-type="pmid">11740561</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>S&#x000fc;dhof</surname><given-names>TC</given-names></name><article-title>Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>24601</fpage><lpage>24611</lpage><pub-id pub-id-type="doi">10.1074/jbc.M402248200</pub-id><pub-id pub-id-type="pmid">15044485</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><name><surname>Freude</surname><given-names>KK</given-names></name><name><surname>Penjwini</surname><given-names>M</given-names></name><name><surname>Davis</surname><given-names>JL</given-names></name><name><surname>Laferla</surname><given-names>FM</given-names></name><name><surname>Blurton-Jones</surname><given-names>M</given-names></name><article-title>Soluble amyloid precursor protein induces rapid neural differentiation of human embryonic stem cells</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>24264</fpage><lpage>24274</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.227421</pub-id><pub-id pub-id-type="pmid">21606494</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>KA</given-names></name><name><surname>Suh</surname><given-names>YH</given-names></name><article-title>Pathophysiological roles of amyloidogenic carboxy-terminal fragments of the beta-amyloid precursor protein in Alzheimer&#x02019;s disease</article-title><source>J Pharmacol Sci</source><year>2005</year><volume>97</volume><fpage>461</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1254/jphs.CR0050014</pub-id><pub-id pub-id-type="pmid">15821343</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><name><surname>M&#x000fc;ller</surname><given-names>T</given-names></name><name><surname>Concannon</surname><given-names>CG</given-names></name><name><surname>Ward</surname><given-names>MW</given-names></name><name><surname>Walsh</surname><given-names>CM</given-names></name><name><surname>Tirniceriu</surname><given-names>AL</given-names></name><name><surname>Tribl</surname><given-names>F</given-names></name><name><surname>K&#x000f6;gel</surname><given-names>D</given-names></name><name><surname>Prehn</surname><given-names>JH</given-names></name><name><surname>Egensperger</surname><given-names>R</given-names></name><article-title>Modulation of gene expression and cytoskeletal dynamics by the amyloid precursor protein intracellular domain (AICD)</article-title><source>Mol Biol Cell</source><year>2007</year><volume>18</volume><fpage>201</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">17093061</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>ML</given-names></name><name><surname>Hong</surname><given-names>ST</given-names></name><article-title>Early phase of amyloid beta42-induced cytotoxicity in neuronal cells is associated with vacuole formation and enhancement of exocytosis</article-title><source>Exp Mol Med</source><year>2005</year><volume>37</volume><fpage>559</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">16391517</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><name><surname>Costa</surname><given-names>RO</given-names></name><name><surname>Ferreiro</surname><given-names>E</given-names></name><name><surname>Martins</surname><given-names>I</given-names></name><name><surname>Santana</surname><given-names>I</given-names></name><name><surname>Cardoso</surname><given-names>SM</given-names></name><name><surname>Oliveira</surname><given-names>CR</given-names></name><name><surname>Pereira</surname><given-names>CM</given-names></name><article-title>Amyloid &#x003b2;-induced ER stress is enhanced under mitochondrial dysfunction conditions</article-title><source>Neurobiol Aging</source><year>2011</year><volume>33</volume><fpage>824</fpage><comment>e5-824.e16</comment><pub-id pub-id-type="pmid">21704433</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><name><surname>Urase</surname><given-names>K</given-names></name><name><surname>Momoi</surname><given-names>T</given-names></name><name><surname>Fujita</surname><given-names>E</given-names></name><name><surname>Isahara</surname><given-names>K</given-names></name><name><surname>Uchiyama</surname><given-names>Y</given-names></name><name><surname>Tokunaga</surname><given-names>A</given-names></name><name><surname>Nakayama</surname><given-names>K</given-names></name><name><surname>Motoyama</surname><given-names>N</given-names></name><article-title>Bcl-xL is a negative regulator of caspase-3 activation in immature neurons during development</article-title><source>Brain Res Dev Brain Res</source><year>1999</year><volume>116</volume><fpage>69</fpage><lpage>78</lpage></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><name><surname>Roth</surname><given-names>KA</given-names></name><name><surname>Kuan</surname><given-names>C</given-names></name><name><surname>Haydar</surname><given-names>TF</given-names></name><name><surname>D&#x02019;Sa-Eipper</surname><given-names>C</given-names></name><name><surname>Shindler</surname><given-names>KS</given-names></name><name><surname>Zheng</surname><given-names>TS</given-names></name><name><surname>Kuida</surname><given-names>K</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name><name><surname>Rakic</surname><given-names>P</given-names></name><article-title>Epistatic and independent functions of caspase-3 and Bcl-X(L) in developmental programmed cell death</article-title><source>Proc Natl Acad Sci USA</source><year>2000</year><volume>97</volume><fpage>466</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.1.466</pub-id><pub-id pub-id-type="pmid">10618441</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><name><surname>Luetjens</surname><given-names>CM</given-names></name><name><surname>Lankiewicz</surname><given-names>S</given-names></name><name><surname>Bui</surname><given-names>NT</given-names></name><name><surname>Krohn</surname><given-names>AJ</given-names></name><name><surname>Poppe</surname><given-names>M</given-names></name><name><surname>Prehn</surname><given-names>JH</given-names></name><article-title>Up-regulation of Bcl-xL in response to subtoxic beta-amyloid: role in neuronal resistance against apoptotic and oxidative injury</article-title><source>Neuroscience</source><year>2001</year><volume>102</volume><fpage>139</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/S0306-4522(00)00458-9</pub-id><pub-id pub-id-type="pmid">11226677</pub-id></mixed-citation></ref></ref-list></back></article>